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Abstract 
Human cytomegalovirus (HCMV) is a member of the subfamily of 
Beta-herpesviridae that establishes latency in human hematopoietic progenitor cells, 
myeloid progenitor cells and monocytes. While the serological positive population is 
prevalent worldwide, this virus does not cause severe symptoms in 
immunocompetent individuals. However, in immunocompromised patients and 
developing fetuses, this virus can cause serious morbidity and mortality. In light of 
many chronic diseases in the modern world leading to immunodeficiency and organ 
transplants, the importance of HCMV in medical research and public health is rising. 
Although it is known that HCMV establishes latency after primary infection, the 
molecular mechanism(s) that controls latent/lytic switch remains elusive. In addition, 
there is limited knowledge about stimuli that could induce the myeloid cells to support 
HCMV lytic phase.  
In this thesis, we studied the effect of vitamin D, a hormone produced by human 
body or acquired from diet, on HCMV replication in peripheral monocytes and THP-1 
cells. We found that vitamin D induces monocyte differentiation to facilitate HCMV 
replication, and instead of causing a direct up-regulation of HCMV immediate-early 
gene promoter (MIEP) activity as phorbol 12-myristate 13-acetate (PMA) treatment, 
the vitamin D induced monocyte differentiation causes an open chromatin structure 
around MIEP enhancer region of HCMV genome which also happens in PMA treated 
iii 
monocytes. 
In Chapter III of the thesis, we examined the Gαq dependent signaling pathways 
triggered by herpesviruses encoded G protein-coupled receptors by using Gαq 
specific inhibitor (YM-254890). We found that the inositol triphosphate accumulation 
triggered by US28 and M33 can be blocked by the inhibitor but the inositol 
triphosphate accumulation initiated by ORF74 cannot be suppressed by the inhibitor. 
In addition, CREB and NFAT activated by US28 and M33 can also be inhibited by the 
inhibitor, showing that they are Gαq dependent. However, for both US28 and M33, 
NF-κB is Gαq independent. Although ORF74 activates the same downstream 
signaling molecules including CREB, NFAT, and NF-κB, none of these is activated by 
Gαq dependent signal.  
Finally, in Chapter IV of this thesis, we study the expression and function of US28 
in THP-1 cells and monocytes. Our data showed that US28 protein is expressed in 
infected THP-1 cells, and that ectopic expression of US28 kindles Gαq dependent 
inositol triphosphate accumulation in THP-1 cells. In addition, the US28 triggered 
constitutive Gαq signal negatively regulates random migration and chemotaxis, and 
promotes THP-1 cells to adhere to endothelial cells though Gαq-PLCβ-PKC signal 
axis. 
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Introduction to human cytomegalovirus, pathogenesis, and disease  
Human cytomegalovirus (HCMV) is a β-herpesvirus that can infect a broad spectrum 
of cell types(1), and about 50-70% of worldwide population is serologically positive for 
HCMV(2,3). HCMV is an enveloped double stranded DNA virus with a genome size of 
235 kilobase (kb) pairs(4). While in immunocompetent individuals HCMV infection 
does not cause severe symptoms(5), in immunocompromised patients HCMV can 
cause devastating symptoms such as pneumonia, retinitis and chronic graft 
rejection(6-8).  
HCMV primary infection is also a leading cause of congenital defects. In the 
United States, about 1 in 150 children are born with congenital HCMV infection, and 
about 1 in 5 of these children born with congenital HCMV infection will have 
permanent medical sequelae(9-11). Although HCMV was first discovered over six 
decades ago (12,13), no vaccine for this virus is available (14,15). The development 
of an anti-CMV vaccine remains the highest priority according to the Institute of 
Medicine at the National Academy of Science(16). While drugs such as ganciclovir 
and valganciclovir are commonly used to treat HCMV infection, these drugs can lead 
to serious side effects, and the appearance of drug resistant viral strains is common 
(17). Therefore, more detailed studies of HCMV gene products and their effects on 
viral pathogenesis are critical if we are going to develop improved treatments for this 
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virus.  
Similar to the other herpesviruses such as Herpes Simplex Virus and 
Epstein-Barr Virus, HCMV can establish latency after primary infection(18). The 
reservoir for HCMV latency is hematopoietic and myeloid progenitor cells and 
monocytes(19). Since no infectious virus is produced during the latent phase and viral 
reactivation can lead to devastating HCMV disease in immunocompromised 
individuals(20), it is essential to understand the mechanisms that the virus uses to 
regulate latency and targeting the lytic switch could be a viable approach for the 
generation of new therapies that could intervene with the virus production. Although 
some viral and cellular factors are known to be involved in the control of the latent/lytic 
Figure 1. Model depicting human cytomegalovirus (HCMV) latent and lytic phases 
in myeloid cells. 
HCMV enters the latent phase after infecting hematopoietic stem cells, common 
myeloid progenitor cells, granulocyte-macrophage progenitor cells, and monocytes. 
When monocytes differentiate into macrophages or mature dendritic cells, HCMV 
commonly reactivates. Macrophages and mature dendritic cells infected de novo 
with HCMV also support permissive infection. The molecular mechanisms that trigger 
HCMV reactivation and/or allow permissive infection in macrophages and mature 
dendritic cells are still not fully understood.   
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switch (21-23), the exact mechanisms remain unresolved. Moreover, while allogeneic 
stimulation has been shown to trigger HCMV reactivation(24), the complete repertoire 
of stimuli that can initiate viral reactivation and prime cells to support permissive 
infection remains unknown (Figure 1). 
 
Hypotheses and aims of the thesis 
In this research, we hypothesized that there could be unidentified physiological 
factors present in circulatory system that modulate latent/lytic phase switching in 
HCMV infected myeloid cells. Moreover, we speculated that YM-254890, a Gαq/11 
specific inhibitor (25), could be used to dissect signals initiated by herpesvirus 
encoded G protein-coupled receptors (GPCRs). Lastly, based on previous research 
showing that the HCMV encoded GPCR US28 is transcribed during latency (26-28), 
we hypothesized that US28 protein is expressed during viral latency, and that the 
signals triggered by US28 could alter the biology of monocytes to facilitate viral 
dissemination. 
Based on our stated hypotheses, we explored the following three specific aims. 
The first aim of this thesis is to identify additional factors that can facilitate HCMV lytic 
phase replication in myeloid cells. The identification of such factors will give insight 
into the mechanisms that facilitate the latent/lytic switch and also provide an 
appropriate platform to examine the functional activity of HCMV gene products such 
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as the viral G-protein coupled receptors (vGPCRs) in infected myeloid cells.  
1,25-dihydroxyvitamin D3 (Vitamin D) is a natural hormone produced by the 
human body, which can also be obtained from diet (29-31). While vitamin D has long 
been appreciated for its role in regulating the homeostasis of calcium and 
phosphorus(32,33), a variety of more recent studies have also shown that vitamin D 
can regulate both innate and adaptive immunity and promote monocyte-macrophage 
differentiation(34-36), thus facilitating anti-bacterial and anti-viral responses(37-39). 
While Vitamin D action can certainly be thought of as anti-microbial under some 
circumstances, the differentiation of myeloid cells is an important factor for the 
initiation of HCMV permissive infection and thus vitamin D may actually favor lytic 
HCV replication. Since there is no precedent for the effect of vitamin D on HCMV 
replication in myeloid cells, one of the goals of the thesis is to examine this question. 
In this study, we used peripheral blood monocytes and THP-1 cells, a promonocytic 
cell line(40), to investigate the effect of vitamin D. While phorbol 12-myristate 
13-acetate (PMA), a synthetic molecule that resembles diacylglycerol by activating 
protein kinase C(41), can differentiate THP-1 cells into macrophage-like cells and 
support HCMV lytic phase(42), natural stimuli that can trigger HCMV lytic infection in 
primary monocytes and THP-1 cells is of major interest. Since the sTHP-1 cell is 
commonly used as a myeloid model for HCMV studies (43,44), grows easily in tissue 
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culture, and is amenable to genetic manipulation/gene knockdown approaches(45,46), 
it would be interesting to determine whether Vitamin D can drive HCMV lytic 
permissive infection in both primary monocytes and in THP-1 cells. Moreover, since 
Vitamin D and TGF-β synergize to enhance myeloid cell differentiation (47-49), it is 
possible that Vitamin D combined with TGF-β could have an additional influence on 
HCMV replication in myeloid cells. Finally, to determine whether vitamin D can affect 
cytomegalovirus replication in vivo, wildtype and VDR-/- Balb/c mice were infected with 
MCMV (strain pARK25/K181), and spleens were analyzed for viral replication and 
pathology at 4 days post-infection. 
The second aim of the thesis is to use the Gαq specific inhibitor YM254890 (25) 
to dissect the signaling pathways triggered by viral G protein coupled receptors 
(vGPCRs) encoded by herpesviruses including human cytomegalovirus (HCMV), 
murine cytomegalovirus (MCMV) and Kaposi’s Sarcoma-associated herpesvirus 
(KSHV). Previous studies have demonstrated that these vGPCRs are similar in 
structure to mammalian chemokine receptors (50), while they have the ability to bind 
to multiple chemokines. Unlike chemokine receptors that trigger signal transduction 
only after binding to ligands, these herpesvirus vGPCRs can trigger ligand 
independent signals (51). ORF74 is a GPCR encoded by KSHV (52) that may play a 
role in viral reactivation (53) and has oncogenic properties in that it is a strong inducer 
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of angiogenesis(54,55). US28, a HCMV encoded vGPCR(56), has been shown to 
promote smooth muscle cell migration(57,58) and function as a chemokine sink which 
may play a role in evasion of immune response(59). The MCMV encoded M33 has 
been known to profoundly affect viral growth in salivary glands of persistently infected 
mice (60).  
Given the association of the herpesviruses and their encoded vGPCRs with a 
variety of disease processes (50,51), the identification of small molecules that can 
target the vGPCRs and inhibit their signaling could be candidates for next generation 
antivirals(61,62). It is known that these three vGPCRs can all constitutively activate 
phospholipase C and cause accumulation of the second messenger IP3 
accumulation(63-65). Moreover these vGPCRs share the ability to activate a similar 
repertoire of downstream signaling molecules including the CREB, NFAT, and NF-κB 
transcription factors (63,66,67). However, whether CREB, NFAT, and NF-κB are all 
activated through Gαq is unknown. Whether or not the activation of these 
transcription factors contributes to the biological activities of the vGPCRs is also 
unknown. Therefore, we used the Gαq specific inhibitor YM-254890 to examine which 
downstream signaling molecule are Gαq dependent. While studies have shown that 
vGPCRs are somewhat promiscuous in coupling to Gα subunits in a context 
dependent fashion (65,68,69), our studies with the YM-254890 compound will provide 
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important clarity regarding the signaling mechanisms used by the vGPCRs. Moreover, 
as some Gα subunits show tissue specific expression patterns (70,71) inhibitors like 
YM-254890 could be used to determine whether the signaling triggered by the 
vGPCRs in different cell types utilizes the same or different G-protein. Thus, the 
characterization of the activities of the YM-254890 compound towards the vGPCRs 
could prove to be a quick and valuable reagent that could be used to determine the 
mechanisms of vGPCR signaling in different cell types. 
The Third aim of the thesis is to examine expression, signaling, and functional 
effects of US28 in myeloid cells. Our studies will entail the use of both primary 
monocytes and THP-1 cell line where appropriate. According to previous studies, it is 
known that US28 transcripts can be detected in latently infected THP-1 cells, 
hematopoietic progenitor cells, and granulocyte-macrophage progenitor cells 
(26-28,72). However, whether US28 protein is expressed in these cells and what 
function(s) US28 possesses in these cells remains unknown. We used an HCMV 
TB-40E mcherry strain that encodes a US28-FLAG fusion protein (64,73) to infect 
THP-1 cells, and took advantage of high-affinity anti-FLAG reagents to purify US28 
protein from infected cells and confirmed its identity by western blot. HCMV TB-40E 
strain is a strain that demonstrates enhanced tropism for endothelial and myeloid cells 
in comparison to the lab adapted strains such as AD169 and Towne (74,75). Unlike 
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the AD169 and Towne strains which have multiple deletions in the genome, TB-40E 
strain contains an intact ULb’ region, a genomic segment that is essential for efficient 
entry into endothelial and myeloid cells and latency establishment in the latter 
(74,76,77).  
To study the function and signaling of US28 in THP-1 cells, we used lentivirus to 
deliver tetracycline inducible lentiviral vectors expressing US28 wildtype or US28 
mutants in THP-1 cells. While US28 triggers constitutive Gαq-dependent signals in 
various cell types, whether US28 signals similarly in the myeloid setting remains 
unknown. Inositol phosphate (IP3) accumulation assays will be executed in 
combination with pharmacological inhibitors (YM-254890, etc) to study the signals 
generated by US28 in THP-1 cells. Chemokine receptors (to which US28 is most 
similar) are known to regulate cellular migration(78), and since US28 has been shown 
to promote cell migration in vascular smooth muscle cells and macrophages(58,79) it 
will be interesting to examine the effects of US28 on monocytes in our system. We 
used standard Boyden-Chamber based transwell migration assays to examine the 
effect of US28 on both chemokinesis (spontaneous cellular movement) and 
chemotaxis (ligand directed cellular movement). Monocytes are believed to play an 
important role in HCMV dissemination by adhering to endothelial cells and 
extravasating into surrounding tissue, where they can differentiate into macrophages 
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and initiate viral reactivation (80,81). Thereby, it is possible that US28 could influence 
monocyte-endothelial adhesion. Monocyte-endothelial adhesion assays were 
performed to determine the effect of US28 on monocyte adhesion.  
In summary, focusing on the myeloid setting, we have studied the effects of 
Vitamin D on HCMV lytic replication and examined the signaling and functional 
activities of the HCMV vGPCR US28. We have also characterized and validated the 
effects of the pharmacological inhibitor YM-254890 on herpesvirus vGPCR signaling 
and incorporated the use of this compound into our studies on US28 function in 
myeloid cells. We hope that the results from these studies will offer insight into HCMV 
pathogenesis and provide useful information regarding our understanding of the 
HCMV latent/lytic switch and the signaling pathways triggered by viral GPCRs. Finally, 
we hope that our studies provide an appropriate framework from which to begin to 
think about using novel compounds like YM-254890 to influence viral replication and 
possibly decrease the frequency and extent of HCMV associated disease. 
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Abstract 
Human cytomegalovirus (HCMV) resides in a latent form in hematopoietic progenitors 
and undifferentiated cells within the myeloid lineage. Maturation and differentiation 
along the myeloid lineage triggers lytic replication. Here, we used peripheral blood 
monocytes and the monocytic cell line THP-1 to investigate the effects of 
1,25-dihydroxyvitamin D3 on HCMV replication. Interestingly, 1,25-dihydroxyvitamin 
D3 induces lytic replication marked by up-regulation of HCMV gene expression and 
production of infectious virus. Moreover, we demonstrate that the effects of 
1,25-dihydroxyvitamin D3 correlate with maturation/differentiation of the monocytes 
and not by directly stimulating the MIEP. These results are somewhat surprising as 
1,25-dihydroxyvitamin D3 typically boosts immunity to bacteria and viruses rather 
than driving the infectious life cycle as it does for HCMV. Defining the signaling 
pathways kindled by 1,25-dihydroxyvitamin D3 will lead to a better understanding of 
the underlying molecular mechanisms that determine the fate of HCMV once it infects 
cells in the myeloid lineage.   
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Introduction 
Human cytomegalovirus (HCMV) is a β-herpesvirus that spreads broadly 
throughout the human population (1). In general, about 50-70% of people are 
serologically positive for HCMV worldwide (3). Although in immunocompetent 
individuals HCMV infection is typically asymptomatic, in the case of congenital 
infection, the virus can cause severe neurological sequelae such as deafness and 
developmental defects following infection of the fetus (9,10). In immunocompromised 
individuals, including those with HIV/AIDS or those receiving organ transplants, 
HCMV can cause devastating morbidity and mortality including pneumonia, retinitis, 
and transplant rejection (6-8). Moreover, many studies have shown that HCMV can be 
associated with chronic diseases such as atherosclerosis and hypertension, cancer, 
and autoimmune disease (82-85). Therefore, understanding the biology of HCMV 
infection is both clinically relevant and intensively studied with regards to potential 
pharmacological intervention. Like other herpesviruses, HCMV can establish latency 
in the human body, thus making the eradication of the virus from infected individual a 
difficult task (18,86). The cellular reservoirs for HCMV latency include hematopoietic 
stem cells, common myeloid progenitor cells, and monocytes (72,87-89). Deciphering 
the mechanisms that regulate the latent/lytic switch in HCMV infected cells could lead 
to the identification of novel therapeutics that could be used to regulate latency. 
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Previous studies have indicated that both viral and cellular factors are involved in the 
control of latent and lytic cycles in myeloid progenitors and monocytes 
(21-23,80,90-92); however, the molecular mechanisms remain unresolved, and it is 
highly probable that there are numerous cellular and viral regulatory factors that have 
yet to be identified. In light of this, further investigation of the mechanisms and factors 
that influence the switch between HCMV latency and lytic replication in clinically 
relevant myeloid cell types is needed. 
It is known that the developmental maturation of monocytes into macrophages 
and dendritic cells can reactivate HCMV from latency leading to the production of new 
infectious virus (24,80,92-95). In addition, there are various extracellular stimuli (i.e. 
PMA) that can trigger monocyte to macrophage differentiation (96-101) and some of 
these stimuli have also been shown to directly induce the HCMV immediate-early 
gene promoter, which is essential for induction of the HCMV lytic cycle (102-104). 
Since the activities of these stimuli appear to be multi-factorial, it is difficult to 
determine if the major influence of these stimuli on lytic replication is induction of the 
IE promoter, promotion of cellular maturation/differentiation or a combination of both 
activities. THP-1 cells are a monocytic cell line that is commonly used in combination 
with primary blood derived monocytes to study the interaction between HCMV and 
myeloid cells and gain insight into the latent/lytic switch (44,105). It is well known that 
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HCMV enters latency or a quiescent state in undifferentiated THP-1, and the virus 
typically enters into the lytic cycle after it infects phorbol 12-myristate 13-acetate 
(PMA) treated THP-1 cells (42,106). As a consequence, PMA is a reagent of choice 
used to promote myeloid differentiation in studies aimed at inducing lytic replication in 
in vitro systems. However, PMA is a synthetic compound resembling diacylglycerol 
(DAG) that is capable of activating a broad range of cell signaling pathways 
(41,107,108). In this research we sought to identify additional physiologically relevant 
compounds that could trigger both monocyte differentiation and HCMV lytic infection. 
Vitamin D3 is a hormone that is produced by the human body and acquired in a 
supplemental fashion through diet (29-31). The most well-known effects of vitamin D3 
and its active metabolite 1,25-dihydroxyvitamin D3 are to regulate homeostasis of 
calcium and phosphorus and promote bone development through interaction with the 
vitamin D receptor (VDR), a member of the nuclear receptor family of transcription 
factors (32,33). Interestingly, blood leukocytes robustly express the VDR and results 
of studies performed in vitro in human myeloid cell lines and ex vivo in murine bone 
marrow cells have demonstrated that 1,25-dihydroxyvitamin D3 has the ability to 
induce monocyte-macrophage differentiation (34,35,109-113). It is therefore not 
surprising that 1,25-dihydroxyvitamin D3 has been demonstrated to exhibit 
antibacterial and antiviral effects (37-39,114). The importance of 
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1,25-dihydroxyvitamin D3 in regulation of immune system function has been further 
highlighted by studies which suggest that 1,25-dihydroxyvitamin D3 or synthetic 
analogues of 1,25-dihydroxyvitamin D3 could be used as potent candidates for the 
treatment for autoimmune diseases, infectious diseases and anticancer therapies 
(115-117). Nonetheless, the effect of 1,25-dihydroxyvitamin D3 on HCMV replication 
in monocytes and macrophages remains unknown. Therefore, we explored the 
possibility that peripheral blood monocytes and THP-1 cells could be used to 
determine the effect of 1,25-dihydroxyvitamin D3 on HCMV replication in myeloid 
cells. According to the results of previous studies, 1,25-dihydroxyvitamin D3 treatment 
induces THP-1 cells to differentiate into mature monocytes, with high CD14 
expression (34,118,119) and therefore we hypothesized that we also could use this 
model to study HCMV replication in 1,25-dihydroxyvitamin D3 treated cells that are in 
the transition from the promonocytic to macrophage stages. 
Interestingly, we found that the HCMV lytic phase can be induced in 
1,25-dihydroxyvitamin D3 treated primary monocytes and in THP-1 cells with 
infectious virus being produced by these cells. In contrast to PMA treated cells, 
1,25-dihydroxyvitamin D3 does not have a direct effect on the HCMV immediate-early 
gene promoter in reporter gene assays suggesting that the predominant effect of 
1,25-dihydroxyvitamin D3 is to drive differentiation and not necessarily to directly 
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stimulate IE promoter activity. When 1,25-dihydroxyvitamin D3 is combined with PMA 
to differentiate THP-1 cells, no additive effect on HCMV replication is observed. These 
results demonstrate that 1,25-dihydroxyvitamin D3 induces a set of differentiation 
related signaling pathways that creates a favorable cellular milieu for HCMV lytic 
infection. Moreover, our results suggest that clinical/dietary supplementation with 
vitamin D3 could be problematic in patients susceptible to reactivation-based HCMV 
disease. 
 
Materials and Methods 
General Reagents. 1,25-dihydroxyvitamin D3 and phorbol 12-myristate 13-acetate 
(PMA) were purchased from Sigma-Aldrich. APC conjugated anti-human CD14, 
anti-human CD11b, anti-human CD54, anti-human CD36 antibodies and PE 
conjugated anti-mouse IgG1 antibodies were obtained from eBioscience. Anti-CMV 
IE1/IE2 antibody (mAb810) and an Alexa Fluor® 488 conjugated version of mAB810 
were purchased from Millipore.  Anti-CMV UL44 antibody (mAb 25G11, IgG1 
isotype) was a kind gift of John Shanley, and anti-CMV pp65 antibody was obtained 
from Virusys Corporation. 
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Cell culture and differentiation of THP-1 cells. THP-1 cells were maintained in 
RPMI-1640 (Roswell Park Memorial Institute-1640) supplemented with 10% FBS, 100 
IU/ml penicillin and 100 µg/ml streptomycin at 37°C in 5% CO2. THP-1 cells were 
passaged every 3 days to maintain the cell density between 0.2x106 and 1x106 
cells/ml. Human foreskin fibroblasts (HFFs) were maintained in DMEM (Dulbecco 
Modified Eagle’s Medium) supplemented with 10% Fetal Clone III serum, 100 IU/ml 
penicillin and 100 µg/ml streptomycin at 37°C in 5% CO2. THP-1 cells were treated 
with 80nM PMA or 100nM 1,25-dihydroxyvitamin D3 for three days to induce cellular 
maturation/differentiation. 
 
Propagation and purification of virus. The HCMV TB40E-mCherry(3XFLAGUS28) 
virus was generously provided by Dr. Christine O’ Connor from the Cleveland Clinic 
(64,73). This virus was characterized and demonstrated to grow with similar kinetics 
and to similar titers as does HCMV TB40E. To propagate virus, HFFs were infected 
with TB40E viruses at an m.o.i. of 0.04. Viral supernatant was harvested at days 9, 
11, and 13 post-infection. Cell Culture supernatant containing virus was centrifuged at 
1800xg for 3 minutes at 21°C to remove cellular debris. The clarified supernatant was 
overlayed on a 20% D-sorbitol/1mM MgCl2 cushion and subjected to 
ultracentrifugation at 24,000 rpm for 1hr at 21°C. Supernatant was decanted, and the 
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viral pellet was resuspended in RPMI-1640 culture media. Viral supernatant was 
aliquoted and stored at - 80°C. 
 
Isolation of monocytes from peripheral blood of normal donors. Blood was 
diluted 2 fold with Dulbecco’s Phosphate-Buffered Saline (DPBS) containing 2 mM 
EDTA. Diluted blood was carefully layered over 15 ml of Ficoll-paque® PLUS in a 50 
ml conical tube. Conical tubes were centrifuged at 400xg for 30-40 minutes at 20°C in 
a swinging bucket rotor without brake. After centrifuge, the upper layer was aspirated, 
leaving buffy coat containing the mononuclear cell layer undisturbed at interphase. 
The buffy coat was transfered to a clean tube, and fresh DPBS with 2 mM EDTA was 
added to fill the tubes. The cells were centrifuged at 300xg for 10 minutes at 20°C. 
Then supernatant was carefully removed. In order to remove platelets, cells were 
resuspended in 50 ml of DPBS with 2 mM EDTA, and centrifuged at 200xg for 10-15 
minutes at 20°C. The supernatant was removed afterward.  The wash step was 
repeated once to further deplete platelets. Cells were resuspended in 80 µl of buffer 
(DPBS containing 0.5% BSA and 2 mM EDTA) per 107 cells.  20 µl of CD14 
MicroBeads (Miltenyi Biotec) was added per 107 cells, and cells were incubated in the 
cold room (2-8°C) for 30 minutes. After incubation, cells were washed by adding 1-2 
ml of buffer (DPBS containing 0.5% BSA and 2 mM EDTA) per 107 cells, and 
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centrifuged at 300xg for 10 minutes. 108 cells were resuspended in 500 µl of buffer, 
and passed through LS Column (Miltenyi Biotec). The column was washed 3 times 
with buffer.  The column was removed from MACS Separator (Miltenyi Biotec), and 
cells were flushed out by firmly pushing the plunger into the column. 
 
Culture and infection of primary peripheral blood derived monocytes.  CD14+ 
monocytes isolated as described above were resuspended in RPMI-1640 
supplemented with 10% FBS, 100 IU/ml penicillin and 100 µg/ml streptomycin. Cells 
were then cultured in 1,25-dihydroxyvitamin D3 (100 nM),  PMA (80 nM) or the 
appropriate vehicle control (EtOH or DMSO)  for 2 days at 37°C in 5% CO2. After 2 
days of culture in 1,25-dihydroxyvitamin D3, PMA or vehicle, viral supernatant was 
added at a MOI of 10, and cells were incubated overnight. After overnight incubation 
with virus, cells treated with vehicle or 1,25-dihydroxyvitamin D3 were pelleted by 
centrifugation, viral inocula were removed, and cells were treated with 1X trypsin for 5 
minutes to remove attached but un-internalized virions (120).  Cells were then 
resuspended in fresh RPMI supplemented as described above and cultured for 4-6 
days. In the case of the PMA treated cells that were adhered to the culture plates, viral 
inocula were aspirated, cells were washed thoroughly with DPBS, fed with fresh RPMI 
and supplements and cultured for 4-6 days. 
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HCMV infection of THP-1 cells. THP-1 cells were infected with HCMV 
TB40E-mCherry (3XFLAGUS28) at MOIs as indicated in the figure legends. After the 
viral supernatant was added, cells were centrifuged at 21°C and 1000xg for 30 
minutes to enhance infectivity. After overnight culture, cells were spun down and the 
inocula were removed. Cells were incubated in 1X trypsin for 5 minutes to remove 
attached but un-internalized virions (120). The trypsin reactions were neutralized by 
adding equal volumes of fresh culture media. The supernatant is aspirated, and cells 
were resuspended in fresh culture media. Because the PMA-differentiated cells firmly 
adhere to the plates, the centrifuge step is omitted from infection protocol. After 
overnight culture, culture media were removed and cells were washed with 1X DPBS, 
and fresh media were added to the cells. 
 
Western blot analysis of HCMV gene expression. 1x106 infected THP-1 cells were 
lysed in NP-40 cell lysis buffer (50 mM HEPES pH7.4, 0.5% NP-40, 250 mM NaCl, 
20% glycerol, 2 mM EDTA, 100 µM Sodium Orthovanadate, 1 mM Sodium Fluoride, 
1X complete Mini protease inhibitor). Cell lysates were sonicated for 20 seconds on 
level 1 using a Sonic Dismembrator Model 100 (Fisher Scientific). Protein 
concentrations for each lysate sample were determined using the Bio-Rad protein 
assay reagent. Lysates were mixed with Laemmli sample buffer, and heated at 100° 
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for 10 minutes. 30 µg of protein was loaded into each lane for electrophoresis. 
Proteins were transferred to nitrocellulose membranes using a semi-dry transfer 
apparatus (Continental Lab Products). Membranes were blocked with 5% non-fat 
dried milk for 1 hour and membranes were incubated with primary antibody at 4° 
overnight. Membranes were washed 3 times with Tris buffered saline with Tween-20 
(TBST) and then incubated with secondary antibody for 2 hours. Membranes were 
washed with TBST 3 times and subjected to antibody detection using the SuperSignal 
West Pico chemiluminescent substrate (Thermo Scientific). Luminescence emitted 
from the membranes was detected by classic blue autoradiography film BX. Films 
were developed by Kodak min-R mammography processor. 
 
MIEP reporter gene construction. The HCMV immediate-early gene promoter (bp 
52586-53162 in GenBank entry AC146907.1) was PCR amplified from FIX-BAC 
bacmid DNA using the following primers. HCMV MIEP promoter forward primer: 
5’-TAACCCGGGTAGTAATCAATTACGGGG-3’, HCMV MIEP promoter reverse 
primer: 5’-TCGAGATCTCTGACGGTTCACTAAACG-3’. PCR amplification was 
performed for 30 cycles, consisting of denaturation at 94°C for 30 seconds, annealing 
at 55°C for 30 seconds, and extension at 72°C for 30 seconds. The HCMV MIEP 
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promoter fragment was cloned into the XmaI and BglII sites of pGL3 and sequenced 
to confirm the identity of the MIEP fragment (Genewiz, Inc). 
 
Luciferase assays. 2X105 THP-1 cells were plated per well in 24-well plates and 
cultured overnight.  For each transfection, 410 ng pcDNA3, 60 ng pGL3-HCMV 
MIEP, 30 ng phRGTK-renilla and 1.5 µl TransIT-2020 was diluted into 50 µl 
RPMI-1640 and incubated for 15 minutes. The incubated transfection reagent was 
then added into each well. 4 hours after transfection, vehicle (ethanol or DMSO), 
1,25-dihydroxyvitamin D3 (100 nM), or PMA (80 nM) was added to the designated 
wells and the cells were incubated for a further 24 hours. Cells were lysed in 200 µl of 
1X passive lysis buffer and 10 µl of the cell lysate was used in luciferase assay 
reactions. 50 µl of Firefly-luciferase substrate was added to cell lysate and luciferase 
activity was measured on a Glomax 20/20 luminometer (Promega). 50 µl Stop & Glow 
solution was added to each reaction, and luminescence of the control reporter 
Renilla-Luciferase was measured. The Firefly-luciferase reading of vehicle control 
(ethanol) was divided by the Renilla-Luciferase reading of vehicle control and that 
value was defined as 1. The fold changes were then determined by dividing the 
luciferase to renilla ratios of the experimental conditions to the ratio of vehicle control. 
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Infectious center assays. 1x105 HFF cells were plated into wells of 12-well plates 
and cultured overnight. Infected THP-1 cells or primary monocytes were harvested at 
six days post-infection and co-cultured with HFFs for 2 days. Culture media was then 
removed and the plates were washed twice with 1X PBS. Cell monolayers were 
covered with overlay media (a 1:1 mixture of 1.5% carboxymethyl cellulose (Sigma), 
and 2X MEM supplemented with 20% FCIII serum, nonessential amino acids, and 
penicillin-streptomycin) and incubated for another 8 days to allow for plaque 
development. Cells were fixed with methanol, stained with 10% Geimsa (Sigma) and 
plaques were counted using a dissecting microscope. 
 
Plaque assays. After infection, culture media from each cell sample was harvested 
on the indicated days, and 10 µl of culture media was added to HFF monolayers 
plated in 12-well plates the previous day. Virus was adsorbed to HFF monolayers for 
3 hours, culture media were removed, and covered with overlay media (a 1:1 mixture 
of 1.5% carboxymethyl cellulose (Sigma), and 2X MEM supplemented with 20% FCIII 
serum, nonessential amino acids, and penicillin-streptomycin) and incubated for 
another 8 days to allow for plaque development. Cells were fixed with methanol, 
stained with 10% Giemsa (Sigma) and plaques were counted using a dissecting 
microscope. 
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Flow cytometry. For cell surface marker analyses, cells were harvested and 
resuspended in 50 µl of a 0.5% BSA/DPBS solution containing 1:200 dilution of the 
appropriate APC-conjugated antibody (CD11b, CD14, etc). Cells were incubated at 
room temperature for 1 hour. Cells were washed with 0.5% BSA/DPBS solution, 
resuspended in fresh DPBS and analyzed by flow cytometry on a BD FACSCalibur. 
For HCMV IE protein staining, cells were harvested, resuspended in 100 µl DPBS and 
1 ml of 70% ice cold EtOH was added to fix the cells. Fixed cells were washed and 
permeabilized with 0.5% BSA/DPBS solution containing 0.5% tween-20. Cells were 
then resuspended in 0.5% BSA/DPBS solution containing 1:200 dilution of Alexa488 
conjugated anti-HCMV IE antibody, and incubated at room temperature for 1 hour. 
Stained cells were washed with 500 µl 0.5% BSA/DPBS solution containing 0.5% 
tween-20. For UL44 and IE co-staining, cells were fixed and permeabilized as above 
and then resuspended in 0.5% BSA/DPBS solution containing 1:10 dilution 
anti-HCMV UL44 antibody. Cells were incubated for 1 hour at room temperature, 
washed as described above and then incubated for 1 hour in 0.5% BSA/DPBS 
solution containing 1:250 dilution of PE-conjugated anti-mouse IgG1 to label the UL44 
primary antibody. UL44 stained cells were then washed and stained for IE proteins as 
described above. After staining, cells were resuspended in DPBS and analyzed by 
flow cytometry. 
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Semi-quantitative PCR for viral DNA copy number. 2x105 THP-1 cells were 
harvested on days 1 and 6 post-infection, and lysed in 100 µl DNA lysis buffer (121) 
containing 20 µg of Proteinase K at 55°C overnight. Proteinase K activity was stopped 
by incubating DNA lysates at 100°C for 15 minutes and DNAs were used for 
semi-quantitative PCR. Primers for HCMV IE amplification: HCMV IE forward 
5’-ATGGAGTCCTCTGCCAAGAGAAAGATGGAC-3’, HCMV IE reverse 
5’-CAATACACTTCATCTCCTCGAAAGG -3’ (122). Primers used for GAPDH 
amplification: GAPDH forward 5’-GAGCCAAAAGGGTCATC-3’, GAPDH reverse 
primer 5’-GTGGTCATGAGTCCTTC-3’ (123). PCR amplification was performed for 30 
cycles, consisting of denaturation at 94°C for 30 seconds, annealing at 55°C for 30 
seconds, and extension at 72° for 30 seconds. Band intensities were measured by 
NIH Image software and calculated as a ratio of HCMV IE DNA over cellular GAPDH 
DNA. 
 
Chromatin Immunoprecipitation. 5X106 cells were harvested at 2 days 
post-infection and fixed in DPBS containing 1% formaldehyde for 10 minutes at room 
temperature. 2.5 M glycine was added to stop the fixation reaction, and cells were 
washed in ice cold DPBS. Cells were lysed in cell lysis buffer (0.5 mM PIPES pH 8, 85 
mM KCl, 0.5% NP40, 1X protein inhibitor cocktail). Nuclei were pelleted by centrifuge 
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and resuspended in 500 µl nuclear lysis buffer (50 mM Tris-HCl pH 8, 10 mM EDTA, 
1% SDS, 1X protein inhibitor cocktail). The lysates were sonicated for six cycles (30 
seconds on/ 30 seconds off) using program 3 on a Sonic Dismembrator Model 100 
(Fisher Scientific). Lysates were then diluted 5 fold in IP dilution buffer (0.01% SDS, 
1.1% Triton-X 100, 1.2 mM EDTA, 16.7 mM Tris-HCl pH8, 167 mM NaCl, 1X protein 
inhibitor cocktail) and pre-cleared with 30 µl sepharose beads for 2 hours at 4°C. 3 µg 
of anti-tri-methylated histone 3 antibody (Millipore) was added into each reaction and 
rotated overnight at 4°. Protein A/G beads were added to each reaction and incubated 
at 4°C for 3 hours to capture primary antibody. Protein A/G beads was pelleted by 
centrifugation and washed with 1X dialysis buffer (2 mM EDTA, 50 mM Tris-HCl pH8, 
0.2% Sarkosyl, 1X protein inhibitor cocktail) 3 times. Bound chromatin fragments were 
eluted using elution buffer (50 mM NaHCO3, 1% SDS). After elution, RNase A and 
NaCl were added to make final concentration of 0.083 mg/ml and 0.2 M respectively 
and the solution was incubated at 65°C overnight to reverse cross-links. 34 µg of 
Proteinase K was added to digest proteins at 45°C for 2 hours. Primers for 
amplification of MIEP enhancer: Forward primer: 
5’-TTGGGCATACGCGATATCTG-3’. Reverse primer: 
5’-GCCTCATATCGTCTGTCACC-3’ (124). The DNA fragments were recovered using 
a Fermentus gel extraction kit and 20 ng of immunoprecipitated DNA was used for 
27 
 
PCR amplification. PCR reaction conditions are the same as mentioned above except 
were performed for 36 cycles. The signal from chromatin immunoprecipitation 
samples were normalized to signal from respective input samples.   
 
Statistical analysis. Results are presented graphically and represent the mean ± S.E. 
of three or more experiments.  The intensities of bands on immunoblots were 
quantified using Image J software. Statistical analyses were calculated with unpaired 
two-tailed Student’s t tests using GraphPad Prism® 6 software. Differences were 
considered significant at p < 0.05. *, **, and *** represent p < 0.05, p < 0.01, and p < 
0.001, respectively. Nonsignificant changes are denoted by n.s., and represent p > 
0.05. 
 
Results 
1,25-dihydroxyvitamin D3 promotes HCMV replication in primary monocytes 
and THP-1 cells 
Vitamin D3 is a natural hormone that is produced by the human body and typically 
supplemented through diet (29-31). In addition to the regulation of the homeostasis of 
calcium and phosphorus (32,125), vitamin D3 has been shown to play multiple roles 
in immune responses including modulating T cell and B cell activity (126), promoting 
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monocyte-macrophage differentiation (36,127), stimulating the anti-bacterial and 
anti-viral effects of macrophages (128,129), and driving lineage commitment of 
hematopoietic progenitor cells (130). Vitamin D3 like other endocrine hormones is 
carried by the circulatory system to various tissues (29), and research has also shown 
that many cells within the immune system have the enzyme that can convert Vitamin 
D3 into its active form, 1,25-dihydroxyvitamin D3 (131-133). Therefore, vitamin D3 
can execute its effects on a wide variety of cells in either an endocrine or paracrine 
fashion (134). HCMV is a β-herpesvirus which can infect myeloid cells and establish 
latent and/or lytic infections within cells of this lineage (19). Although studies have 
shown that allogeneic stimulation or stimulation with cytokines like TNF-α can 
stimulate HCMV IE promoter activity and drive lytic replication in myeloid cells 
(24,102,135), the effect of 1,25-dihydroxyvitamin D3 on HCMV replication in myeloid 
cells remains unexplored. To determine if 1,25-dihydroxyvitamin D3 may influence 
HCMV lytic replication in myeloid cells, we examined the effect of 
1,25-dihydroxyvitamin D3 on the ability of CD14 positive peripheral blood monocytes 
to support lytic replication. Peripheral blood mononuclear cells (PBMCs) from healthy 
anonymous donors were isolated by Ficoll-paque and CD14 positive monocytes were 
subsequently isolated from PBMCs using CD14 magnetic beads (Miltenyi). 
Monocytes were treated with 1,25-dihydroxyvitamin D3 (100 nM) for 2 days and 
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infected with HCMV TB40E at an MOI of 10. On days 4 and 6 post-infection, cells 
were harvested and subsequently co-cultured with human foreskin fibroblasts 
(infectious center assays) to determine whether the infected monocytes were 
producing infectious virus. Interestingly, monocytes treated with 
1,25-dihydroxyvitamin D3 exhibited a 5-8 fold increase in infectious centers over cells 
treated with the vehicle control ethanol (Figure 2A). These data indicate that 
1,25-dihydroxyvitamin D3 treatment can create a milieu in blood monocytes that more 
efficiently supports HCMV virus production. HCMV replication in primary monocytes 
treated with the phorbol ester phorbal 12-myristate 13-acetate (PMA) was similarly 
examined (Figure 2B). PMA is a well-established inducer of HCMV replication in a 
number of systems (42,106). PMA treated cells exhibited a 15-30 fold increase in 
infectious centers over cells treated with the vehicle control DMSO (Figure 1B). Thus, 
for comparison, while it is readily apparent that 1,25-dihydroxyvitamin D3 is a robust 
inducer of HCMV replication in monocytes, the level of replication achieved is not as 
strong as that achieved by the phorbol ester, consistent with what might be expected 
for a natural compound like 1,25-dihydroxyvitamin D3. 
We then sought a model system that could be utilized to provide a more 
mechanistic explanation for this finding. THP-1, an established monocytic cell line and 
model system frequently used in HCMV studies (43,44), was then deployed to further 
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explore the effects of 1,25-dihydroxyvitamin D3 on HCMV lytic replication. Since it is 
well established that PMA can drive HCMV production in THP-1 cells, we again used 
PMA as a control in these experiments (42). THP-1 cells were treated with vehicle 
(ethanol), 1,25-dihydroxyvitamin D3 (100 nM) or PMA (80 nM) for 3 days before 
infection. Cells were then infected with HCMV TB40E at an MOI of 10. On day 6 
post-infection, THP-1 cells were co-cultured with HFFs in infectious center assays. In 
THP-1 cells treated with the ethanol control, only a very low number of plaques were 
detected in infectious center assays, which indicate that THP-1 cells rarely support 
lytic phase replication after HCMV infection (Figure 3). In PMA treated THP-1 cells, 
there was a 40-fold increase in the number of plaques arising in infectious center 
assays supporting early studies that reported the induction of lytic phase replication 
by PMA treatment. Importantly, 1,25-dihydroxyvitamin D3 treatment of THP-1 cells 
resulted in a 10-fold increase in the number of plaques arising in infectious center 
assays. We repeated this experiment and examined infectious center production at 
days 6 and 8 post-infection and obtained similar results, indicating that the difference 
in lytic replication observed between 1,25-dihydroxyvitamin D3 and PMA treated cells 
is not simply the result of a delay in virus replication in the 1,25-dihydroxyvitamin D3 
treated cells (data not shown). Therefore, since 1,25-dihydroxyvitamin D3 can 
promote lytic virus production in both peripheral blood monocytes and in the 
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monocytic cell line THP-1, we conclude that THP-1 cells would provide a viable model 
to recapitulate and further explore the effects of 1,25-dihydroxyvitamin D3 on HCMV 
replication in myeloid cells. 
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Figure 2. 1,25-dihydroxyvitamin D3 promotes HCMV replication in primary peripheral 
blood derived monocytes 
Monocytes were treated with 100 nM 1,25-dihydroxyvitamin D3 (A) or 80 nM PMA (B) 
for 2 days and then infected with HCMV TB40E at a MOI of 10. On 4 days and 6 days post 
infection, cells were harvested and co-cultured with HFF fibroblasts for 2 days. After 2 
days of co-culture, fibroblast monolayers were overlaid with CMC/MEM and incubated 
for 8 days to allow for plaque development. The data represent 4-8 independent 
experiments performed in duplicate. VitD3, 1,25-dihydoxyvitamin D3. * p<0.05, ** 
p<0.01. 
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1,25-dihydroxyvitamin D3 treatment does not influence the ability of HCMV to 
establish an initial infection in monocytes 
Since we found that 1,25-dihydroxyvitamin D3 treatment can dramatically increase 
the number of plaques that arise from THP-1 cells in co-culture infectious center 
assays, we wanted to determine whether this difference could be the result of 
increased infectivity or entry of HCMV virions into 1,25-dihydroxyvitamin D3 treated 
cells. We used semi-quantitative PCR to examine viral genome copy number in cells 
at various time points post-infection (Figure 4). If 1,25-dihydroxyvitamin D3 leads to 
increased infectivity of the monocytes, we would expect to see increased viral DNA 
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Figure 3. 1,25-dihydroxyvitamin D3  promotes  HCMV replication in  the THP-1 
monocytic cell line 
THP-1 monocytes were treated with 1,25-dihydroxyvitamin D3 (100 nM) or PMA (80 
nM) for 3 days and then infected with HCMV TB40E at a MOI of 10. On day 6 
post-infection, cells were harvested and co-cultured with HFF fibroblasts for 2 days. 
After 2 days of co-culture, fibroblast monolayers were overlaid with CMC/MEM and 
incubated for 8 days to allow for plaque development. The data represent five 
independent experiments performed in duplicate. VitD3, 1,25-dihydoxyvitamin D3.  
** p<0.01, *** p<0.001. 
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levels at early time points post-infection. However, at day 1 post-infection, cells 
treated with 1,25-dihydroxyvitamin D3 or PMA exhibited similar viral copy numbers to 
that of vehicle control cells. The results are depicted in Figure 4A and quantitative 
results from six independent experiments are shown in Figure 4B. This result 
suggested that HCMV infects control and 1,25-dihydroxyvitamin D3 treated cells with 
equivalent efficiency. At day 6 post-infection, the PCR signal for viral genomes in 
control THP-1 cells declined while the signal from 1,25-dihydroxyvitamin D3- and 
PMA-treated cells was maintained or increased, consistent with the conclusion that 
1,25-dihydroxyvitamin D3 and PMA treated cells are supporting lytic HCMV 
replication. 
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Figure 4. 1,25-dihydroxyvitamin D3 treatment does not influence HCMV entry  
(A) THP-1 monocytes were treated with 1,25-dihydroxyvitamin D3 (100nM) or PMA 
(80nM) for 3 days and then infected with HCMV TB40E at a MOI of 10. On days 1 and 6 
post infection, DNA from THP-1 cells subjected to the indicated treatments was 
amplified by PCR for HCMV genomes (IE region) or cellular genomes (GAPDH). PCR 
products were visualized by agarose gel electrophoresis. (B) The PCR signals of viral 
DNA were normalized to the signals of GAPDH. Data shown are the means +/- SEM of 
six independent experiments. VitD3, 1,25-dihydroxyvitamin D3. n.s. non-significant, 
*p<0.05, **p<0.01, d.p.i. day post infection. 
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1,25-dihydroxyvitamin D3 treated THP-1 cells are more likely to exhibit IE gene 
expression following infection 
While an equivalent amount of HCMV DNA is initially present following infection of 
control or 1,25-dihydroxyvitamin D3 treated cells, it is clear that the 
1,25-dihydroxyvitamin D3 treated cells support a robust increase in productive HCMV 
replication. Therefore, we next chose to examine HCMV gene expression profiles in 
1,25-dihydroxyvitamin D3 and PMA treated cells. Immediate early (IE) gene 
expression is typically repressed in cells that fail to undergo lytic phase induction, but 
is expressed rapidly after infection in cells capable of supporting lytic replication 
(43,136,137). We examined IE gene expression in cells treated with vehicle control, 
1,25-dihydroxyvitamin D3 or PMA (Figure 4). Flow cytometric staining with 
anti-IE-Alex488 antibodies was performed as this enabled us to assess not only the 
frequency with which IE positive cells arise but also the relative level of IE antigens 
per cell. Infected cells were harvested and examined at day 1 post-infection. 
Compared to vehicle control, 1,25-dihydroxyvitamin D3 treatment resulted in a 
significantly higher percentage of IE positive cells by day 1 post-infection (Figures 5A 
and B). Interestingly, while the number of IE positive cells is significantly increased 
with 1,25-dihydroxyvitamin D3 treatment, there is no difference in the relative IE 
expression per cell as the mean fluorescent intensities are similar when comparing 
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vehicle and 1,25-dihydroxyvitamin D3 treated cells (Figure 5C). PMA, in contrast, 
caused an increase in both the percentage of IE positive cells and relative IE 
expression per cell, suggesting that the mechanisms utilized by 1,25-dihydroxyvitamin 
D3 and PMA to promote lytic replication may be distinct. We did not detect any 
differences in the subcellular localization of IE1/2 when comparing control, 
1,25-dihydroxyvitamin D3, and PMA treated cells indicating that changes in the 
compartmentalization of IE proteins is unlikely to account for the mechanism of 
1,25-dihydroxyvitamin D3 induced HCMV replication (data not shown).  
Taken together, while viral genome copy numbers are initially equivalent, the 
1,25-dihydroxyvitamin D3 treated cells are more highly likely to be capable of initiating 
IE protein production consistent with their ability to progress to the lytic phase 
(Figures 3 and 5). Moreover, while 20-40% of THP-1 cells treated with 
1,25-dihydroxyvitamin D3 or PMA express IE antigens, it is evident that not all cells 
that progress through the IE phase go on to produce infectious virus based on 
infectious center assays, indicating that there are additional blocks subsequent to IE 
expression that control the progression to the lytic phase in HCMV infected myeloid 
cells.  
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Figure 5.  1,25-dihydroxyvitamin D3 treatment increases the percentage of cells 
supporting HCMV IE gene expression 
(A) THP-1 monocytes were treated with 1,25-dihydroxyvitamin D3 (100nM) or PMA 
(80nM) for 3 days and then infected with HCMV TB40E at a MOI of 10. At 1 day 
post-infection, cells were fixed, permeabilized and stained with anti-HCMV IE 
antibody mAB 810-Alexa488. Cells were analyzed by flow cytometry. (B) The 
percentage of IE positive cells at days 1 post-infection is presented graphically. The 
data are derived from four independent experiments including the one depicted in 
panel A  (C) The mean fluorescence intensity of IE positive cells at days 1 
post-infection is presented graphically. The data are derived from four independent 
experiments including the one depicted in panel A. VitD3, 1,25-dihydroxyvitamin 
D3. ** p<0.01,*** p<0.001. 
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HCMV early and late genes are expressed in 1,25-dihydroxyvitamin D3 
stimulated cells 
Although IE expression is important for initiation of lytic infection, the expression of 
early and late genes are needed to complete the lytic phase (138,139). Therefore, the 
expression of early and late HCMV genes was examined by western blot in vehicle 
control, 1,25-dihydroxyvitamin D3 and PMA treated cells (Figures 6A and 6B). For 
these experiments, we analyzed UL44, a processivity factor associated with the viral 
DNA polymerase (140), which is expressed with delayed-early kinetics (141) and 
pp65, a tegument protein that is expressed with late kinetics (142). Vehicle control 
infected cells exhibited undetectable levels of either the delayed early UL44 or late 
pp65 proteins while cells treated with 1,25-dihydroxyvitamin D3 or PMA prior to 
infection showed dramatic upregulation of both UL44 and pp65.  
Representative western blots are depicted in Figure 6A and the results are depicted 
graphically in Figure 6B in which the blots were quantitated and viral protein levels are 
shown relative to the cellular actin protein as a control. To further investigate viral 
gene expression patterns in these cells and determine what percentage of IE positive 
cells progress to the early phase as evidenced by UL44 expression, cells at days 1 
and 4 post-infection were co-stained for IE1/2 and UL44 expression and analyzed by 
flow cytometry (Figure 6C). In vehicle treated cultures, about 7.5% of the cells were IE 
positive at day 1 post-infection, while the percentage of IE positive cells dropped to 
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4.4% at day 4 post-infection. Of the 4.4% IE positive cells at day 4 post-infection only 
11% of cells were UL44 positive (0.5% of the total cellular population). In 
1,25-dihydroxyvitamin D3 treated cultures, approximately 33% of the cells were IE 
positive at day 1 post-infection, while the percentage of IE positive cells declined to 
19% at day 4 post-infection. However, of the 19% IE positive cells, 33% were also 
UL44 positive (6.5% of the total cellular population). In PMA treated cultures, 40% of 
the cells were IE positive at day 1 post-infection and the percentage decreased 
slightly to 38% at day 4 post-infection. Of the 38% IE positive cells, 48% were also 
UL44 positive (18% of the total cellular population). The results of these early and late 
gene expression profiling experiments are also in line with the results of infectious 
center assay and are all consistent with the conclusion that 1,25-dihydroxyvitamin D3 
promotes HCMV lytic replication in myeloid cells. 
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Figure 6. 1,25-dihydroxyvitamin D3 promotes HCMV early and late gene expression 
(A) THP-1 monocytes were treated with 1,25-dihydroxyvitamin D3 (100nM) or PMA (80nM) for 3 
days and then infected with HCMV TB40E at a MOI of 10. At the indicated times post-infection, 
cells extracts were analyzed by western blot for UL44 (early) and pp65 (late) gene expression. 
Western blot analyses demonstrated that UL44 and pp65 are robustly expressed in 
1,25-dihydroxyvitamin D3 and PMA treated cells.  Cell extracts were also analyzed for actin 
expression as an internal control. (B) The results of four independent experiments are shown 
graphically as the ratio of UL44 or pp65 to actin. (C) THP-1 cells treated as described in panel A 
were stained for IE and UL44 proteins at Days 1 and 4 post-infection and analyzed by flow 
cytometry. IE+ cells were gated (left panel in each pair) and then plotted as a function of UL44 
expression (right panel in each pair) to determine the fraction of IE+ cells that have entered into 
the early phase as assessed by UL44 expression. The results shown are representative of 4 
independent experiment. VitD3, 1,25-dihydroxyvitamin D3. , *p<0.05, **p<0.01.  
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1,25-dihydroxyvitamin D3 uses a mechanism distinct from that of PMA to 
promote lytic replication  
Due to the fact that both 1,25-dihydroxyvitamin D3 and PMA can prime THP-1 cells to 
support lytic infection, it would be intriguing to determine if these two reagents deploy 
the same mechanism or if 1,25-dihydroxyvitamin D3 functions in a manner distinct 
from that of PMA. Moreover, since it is clear that IE protein expression is critical for 
the onset of lytic replication, we wished to investigate the effects of 
1,25-dihydroxyvitamin D3 and PMA on IE gene expression in a more detailed manner. 
Based on published reports (124), it has been demonstrated that the HCMV IE 
enhancer region in THP-1 cells after infection is marked by histone 3 lysine 27 
trimethylation (H3K27me3), and that the H3K27me3 mark at the IE enhancer is 
significantly decreased after PMA treatment. H3K27me3 is associated with a closed 
chromatin conformation and silenced gene expression (143), therefore it appears that 
decreased H3K27me3 in the IE region correlates with an open chromatin 
conformation and increased MIEP activity. We wanted to determine whether 
H3K27me3 associated with the IE enhancer is also decreased in 
1,25-dihydroxyvitamin D3 treated cells. Using chromatin immunoprecipitation (CHIP) 
followed by PCR for the IE enhancer region, we find that the IE enhancer region in  
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control cells is in fact modified by H3K27me3 as reported by others (Figure 7A) 
(124,144). However, in both 1,25-dihydroxyvitamin D3 and PMA treated cells the 
CHIP-PCR signal is 4 to 10 fold weaker indicative of decreased H3K27me3 at the IE 
enhancer. Thus, these results are consistent with our analyses of IE1 protein 
expression and suggest that the transition of the MIEP enhancer region into an open 
conformation in 1,25-dihydroxyvitamin D3 treated cells is an important prerequisite for 
the transition to the lytic phase.  
The MIEP contains binding sites for a number of transcription factors that are 
responsive to PMA such as NF-κB and CREB (145), but it is unknown if the MIEP 
would be directly responsive to 1,25-dihydroxyvitamin D3. We cloned the HMCV IE 
promoter from the HCMV-FIX strain into the luciferase reporter pGL3 so that we could 
test whether 1,25-dihydroxyvitamin D3, like PMA would be able to directly stimulate 
the MIEP-luciferase reporter gene.  We transfected THP-1 cells with pGL3-MIEP, 
stimulated cells with either 1,25-dihydroxyvitamin D3 or PMA, and measured 
luciferase activity. Reporter luciferase was internally controlled by comparison to 
constitutively expressed Renilla-luciferase. Interestingly, the Luciferase assay results 
demonstrate that while PMA can directly stimulate MIEP promoter activity, 
1,25-dihydroxyvitamin D3 cannot (Figure 7B). These data are consistent with our flow 
cytometry data in Figure 5C, which indicated that 1,25-dihydroxyvitamin D3 treated 
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cells are more likely to support IE protein expression but do not exhibit increased 
levels of the IE protein on a per cell basis (Figure 5C). Thus, taken together, while 
both 1,25-dihydroxyvitamin D3 and PMA can promote an open conformation of the 
MIEP followed by IE protein production and onset of the lytic phase, the mechanisms 
used by the two inducers are not identical as the effects of PMA can at least be 
partially explained by a direct effect on the MIEP promoter.  
Since the two inducers appeared to not utilize totally overlapping mechanisms 
we investigated whether the effects of 1,25-dihydroxyvitamin D3 would be additive 
regarding the onset of lytic phase. To test this hypothesis, THP-1 cells were treated 
with PMA or PMA + 1,25-dihydroxyvitamin D3 prior to infection. Culture media was 
harvested at multiple time points post-infection and viral titers were assessed by 
plaque assay. Compared to PMA treated cells, 1,25-dihydroxyvitamin D3 plus PMA 
did not show an additive effect as the kinetics and magnitude of the viral growth is the 
same (Figure 8). Thus, while the mechanisms are not totally overlapping, the 
convergence of the two compounds on creating an environment more suitable for IE 
protein expression seems to be a necessary prerequisite leading to the onset of the 
lytic viral life cycle.  
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Figure 7.  1,25-dihydroxyvitamin D3 promotes K27 demethylation of histone H3 
associated with the HCMV IE enhancer region, but does not directly stimulate IE 
promoter activity 
(A) THP-1 monocytes were treated with 1,25-dihydroxyvitamin D3 (100nM) or PMA 
(80nM) for 3 days and then infected with HCMV TB40E at a MOI of 10. At 2 days 
post-infection, chromatin immunoprecipitation was used to examine the K27 
methylation status of histone H3 associated with the HCMV IE enhancer region. The 
results presented are derived from 3 independent experiments. (B) MIEP-luciferase 
activity was assessed in transient reporter gene assays in the presence of 
1,25-dihydroxyvitamin D3 or PMA. MIEP-luciferase activity was normalized to the 
internal control renilla luciferase. The results presented are derived from 3-5 
independent experiments performed in duplicate. VitD3, 1,25-dihydroxyvitamin D3. 
*p<0.05, **p<0.01. 
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The differentiation of THP-1 cells triggered by 1,25-dihydroxyvitamin D3 plays 
an important role in releasing the restriction on HCMV IE expression 
Based on published studies it is clear that 1,25-dihydroxyvitamin D3, like PMA, is an 
inducer of monocyte differentiation and maturation (34,99,118). However, while PMA 
induces the THP-1 cells to mature into a more highly differentiated macrophage-like 
state marked by strong adherence of the cells to plastic, 1,25-dihydroxyvitamin D3 
induces differentiation into a mature monocyte marked by a non-adherent phenotype 
(118). Therefore, we wished to investigate the influence of monocyte differentiation 
properties on 1,25-dihydroxyvitamin D3 induced HCMV replication in the THP-1 
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Figure 8. 1,25-dihydroxyvitamin D3 and PMA do not function in a cooperative 
manner to increase lytic replication  
THP-1 cells were differentiated with PMA (80nM) or PMA (80nM) and 
1,25-dihydroxyvitamin D3 (100nM) for one day, and then infected with HCMV at an 
MOI of 7. Cell supernatants were harvested at the indicated times post-infection and 
viral titers were determined by plaque assay on human foreskin fibroblasts. The 
results indicate that 1,25-dihydroxyvitamin D3 and PMA do not function cooperatively 
to enhance HCMV replication in THP-1 cells. The results are derived from 4 
independent experiments. VitD3, 1,25-dihydroxyvitamin D3.  
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model. Consistent with previous studies (118,119), we observed that PMA but not 
1,25-dihydroxyvitamin D3 induced the appearance of a macrophage phenotype with 
flattened cells tightly adhered to the flask (Figure 9A). Immunostaining for the cell 
differentiation markers CD14, CD11b, CD36, CD54, and CD68 was also performed 
and the results demonstrate that 1,25-dihydroxyvitamin D3 consistently induces 
strong CD14 and moderate CD11b expression while having little to no effect on 
CD36, CD54, and CD68 expression (Figure 9B and Supplemental Figure 1). In 
contrast, PMA induced moderate levels of CD14, while inducing robust levels of 
CD11b, CD36, CD54, and CD68 (Figure 9B and Supplemental Figure 1). These 
results are entirely consistent with those of published studies and are further 
supportive of the conclusion that 1,25-dihydroxyvitamin D3 induces an intermediate 
differentiation phenotype typical of a mature monocyte, while PMA causes a 
terminally differentiated phenotype typical of a macrophage (118,146-148). 
Interestingly, while PMA induces terminal differentiation and halts cellular 
proliferation, 1,25-dihydroxyvitamin D3 treated cells continued to proliferate in 
agreement with previous studies (data not shown) (118). 
   We then asked whether there was a correlation between 1,25-dihydroxyvitamin D3 
promoted differentiation and onset of lytic replication. Since 1,25-dihydroxyvitamin D3 
appeared to not directly stimulate MIEP promoter activity, we hypothesized that the 
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effects of 1,25-dihydroxyvitamin D3 on IE expression might be delayed and only occur 
as the cells differentiated into mature monocytes. To test this postulate, THP-1 cells 
were treated with 1,25-dihydroxyvitamin D3 for different times (6 hours to 3 days) prior 
to infection with HCMV (experimental conditions are depicted graphically in Figure 
10C). Expression of CD14 was monitored throughout the time course to assess 
cellular differentiation and IE positivity was assessed as a measure of the relative 
ability of the cells to promote lytic replication. IE expression was measured at 24 
hours post-infection in all cases. This experimental system enables us to assess the 
expression of the differentiation marker CD14 and the HCMV IE protein in a series of 
cells in different stages of maturation.  CD14 expression as measured by flow 
cytometry peaked at between 1 and 2 days post-stimulation with 
1,25-dihydroxyvitamin D3 (Figure 10A). Interestingly, we did not observe significant 
effects of 1,25-dihydroxyvitamin D3 on IE positivity until 2 days post-stimulation with 
1,25-dihydroxyvitamin D3 (Figure 10B). This finding is consistent with the conclusion 
that 1,25-dihydroxyvitamin D3-induction of lytic HCMV replication correlates with 
1,25-dihydroxyvitamin D3 induced cellular differentiation. Moreover, the lack of a 
significant effect of 1,25-dihydroxyvitamin D3 at early time points argues against a 
direct effect of 1,25-dihydroxyvitamin D3 on the MIEP similar to what we observed in 
reporter assays in Figure 7.  
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Figure 9. 1,25-dihydroxyvitamin D3 and PMA induced THP-1 differentiation is 
phenotypically distinct 
(A) THP-1 cells were treated with 1,25-dihydroxyvitamin D3 (100nM) or PMA 
(80nM) for 3 days and photographed with a Olympus Q Color 5 camera equipped 
with QCapture Pro Software. (B) Cells treated as in panel A were stained with the 
inidcated antibodies and analyzed by flow cytometry. Data from four independent 
experiments is depicted graphically. VitD3, 1,25-dihydroxyvitamin D3. ** p<0.01.  
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Figure 10. The timing and magnitude of 1,25-dihydroxyvitamin D3 induced differentiation  
of THP-1 monocytes is important for supporting HCMV lytic infection 
(A) THP-1 cells  were treated with  1,25-dihydroxyvitamin D3 (100 nM) for indicated 
times and CD14 expression was analyzed by flow cytometry. (B) Cells were treated with 
1,25-dihydroxyvitamin D3 for the indicated times prior to infection with HCMV TB40E. At 24 
hours post-infection cells were fixed, permeabilized and stained with HCMV IE antibody 
mAb810-Alexa488. The results represent flow cytometric analysis of IE positive cells and are 
derived from three independent experiments. (C) Experimental set up for the experiments 
depicted here. Cells were treated for variable lengths prior to infection with HCMV TB40E. 
In all cases IE gene expression was analyzed at 24 hours post-infection. VitD3, 
1,25-dihydroxyvitamin D3. **p < 0.01, ***p < 0.001. 
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Discussion 
In this study, we found that 1,25-dihydroxyvitamin D3, a hormone present in the 
circulatory system and in many tissues (149), can promote HCMV replication in 
primary peripheral blood monocytes and in THP-1 cells. Our data are consistent with 
a mechanism whereby 1,25-dihydroxyvitamin D3 induced HCMV replication involves 
the induction of monocyte differentiation. Based on our data, we propose that 
monocyte maturation/differentiation induced by 1,25-dihydroxyvitamin D3 leads to a 
modification of histone 3 K27 methylation in the HCMV IE enhancer region, which 
results in a conversion to an open chromatin conformation and induction of IE gene 
expression. Moreover, since 1,25-dihydroxyvitamin D3 does not promote cell cycle 
arrest and terminal differentiation of monocyte cell lines in vitro (118), this system 
represents an interesting paradigm that could be utilized to study reactivation of virus 
in model systems. In particular, while previous studies have shown that PMA 
differentiated THP-1 macrophages can support permissive infection, in this study we 
found that monocytes in the transition between mature monocytes and macrophage 
stages, like the state induced by 1,25-dihydroxyvitamin D3,  can also support 
permissive infection. 
 Our work is the first to explore the effect of 1,25-dihydroxyvitamin D3 on 
HCMV in myeloid cells. Although the concentration of 1,25-dihydroxyvitamin D3 used 
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in our study is somewhat higher than the concentrations found in vivo (150), published 
studies have demonstrated that in hematopoietic progenitor cells derived from 
umbilical cord blood, a similar dose of 1,25-dihydroxyvitamin D3 added once a week 
has the same effects on monocyte-macrophage differentiation as does physiological 
concentrations of 1,25-dihydroxyvitamin D3 supplemented daily (150). In this case the 
difference between the two conditions is that high dose treatment causes more rapid 
differentiation and lineage commitment than does physiological concentrations and 
thus the high doses like those used in our study simply facilitate experiments 
performed in an in vitro setting. 
  Although in this research, our main focus is to define the effect of 
1,25-dihydroxyvitamin D3 on HCMV lytic replication in peripheral blood monocytes, an 
equally attractive question to be addressed in the future is to ask what effect 
1,25-dihydroxyvitamin D3 has on HCMV replication in hematopoietic progenitor cells 
(HPCs), a cell type well-known as a reservoir for HCMV latency (72,151). In particular 
does 1,25-dihydroxyvitamin D3 treatment of HPCs affect the ability of HCMV to 
choose a latent or lytic path and would the presence of high concentrations of 
1,25-dihydroxyvitamin D3 promote lytic reactivation? It is known in the HCMV field 
that macrophages and mature dendritic cells can support lytic infection but 
hematopoietic progenitor cells, myeloid progenitor cells and monocytes are cell types 
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known to typically establish a latent infection (19,87). THP-1 cells treated with 
1,25-dihydroxyvitamin D3 do not show a phenotype characteristic of mature 
macrophages and therefore, 1,25-dihydroxyvitamin D3 appears to induce a 
differentiation state in between monocytes and macrophages. Previously, studies of 
HCMV in myeloid cells have focused on hematopoietic progenitor cells (23,152), 
myeloid progenitor cells (27,121), monocytes (22,80,91) or macrophages (153), and 
thus our research offers some additional insight into HCMV replication in cells that are 
transitioning between the monocyte and macrophage stages. Although previous 
studies suggest that HCMV typically enters the lytic phase in mature macrophages 
(42,92,136) our results indicated that cells transitioning between the monocyte and 
macrophage stages can also support lytic infection.  HCMV infection itself has been 
shown to promote monocyte differentiation but the differentiation patterns triggered by 
infection alone are not typically capable of efficiently driving lytic infection (80,91). It is 
highly possible that there is a differentiation threshold that is needed to be passed in 
order to appropriately kindle a lytic infection. 1,25-dihydroxyvitamin D3 treatment may 
prime the cells in the differentiation process, and when infection provides the 
appropriate additional differentiation signals, the threshold is surpassed.  
In these studies we examined whether 1,25-dihydroxyvitamin D3 differentiated 
monocytes can support lytic infection, but as mentioned above an important question 
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to ask in the future is whether 1,25-dihydroxyvitamin D3 may also be involved in the 
reactivation of HCMV from latency. Recently, glucocorticoids have been shown to 
trigger reactivation of HCMV in primary monocytes through direct activation of the IE 
promoter (105). Since there are studies showing crosstalk between glucocorticoids 
and 1,25-dihydroxyvitamin D3 (154), and since 1,25-dihydroxyvitamin D3 can 
enhance glucocorticoid action in human monocytes (155,156), it is reasonable to 
speculate that 1,25-dihydroxyvitamin D3 may also be involved in the regulation of 
HCMV reactivation or work in concert with glucocorticoids in this process. Perhaps 
since the mechanisms of actions appear to be disparate (glucocorticoids directly on 
the MIEP and 1,25-dihydroxyvitamin D3 on cellular differentiation) these two 
hormones may work synergistically to affect HCMV replication and/or reactivation. 
Differentiation of monocytes by 1,25-dihydroxyvitamin D3 appears to robustly 
induce the HCMV lytic phase, but the precise molecular mechanism(s) that regulates 
this activity remain unknown. Based on our studies, we postulate that signaling 
activity and gene expression patterns typically triggered by 1,25-dihydroxyvitamin D3 
to drive monocyte maturation/differentiation are required for HCMV lytic infection to 
proceed. Global comparison of downstream gene expression induced by 
1,25-dihydroxyvitamin D3, PMA and/or glucocorticoids in monocytes by microarray or 
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RNA-seq will be helpful to narrow down the list of candidates, and increase the 
likelihood of identifying the essential molecules that regulate this switch. 
From a clinical perspective, there are many ongoing studies showing that 
1,25-dihydroxyvitamin D3 or its synthetic analogs can have anti-cancer effects, and 
can have beneficial effects on cardiovascular or autoimmune disease (157-159). 
Since there is some evidence supporting a role for HCMV infection in the progression 
of cancers (160,161), cardiovascular and autoimmune diseases (84,162), our study 
could prompt questions regarding whether or not 1,25-dihydroxyvitamin D3 and its 
synthetic analogs should be used therapeutically. In addition, the effect of 
1,25-dihydroxyvitamin D3 on HCMV replication in other cell types including cancer 
cells is still unknown. Moreover, while 1,25-dihydroxyvitamin D3 can have genomic 
and non-genomic effects (163), whether those synthetic analogs have the same effect 
of 1,25-dihydroxyvitamin D3 on HCMV replication is another intriguing question to 
answer and which may provide an important tool to tease out the specific pathways 
involved in lytic induction. 
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Chapter II Appendix:  
Unpublished studies pertaining to Vitamin D and 
Cytomegalovirus Replication 
 
Material and methods 
Vitamin D receptor knockout mice 
VDR knockout mice on a Balb/c background were obtained from Glendon Zinsser at 
the University of Cincinnati. Mice were maintained in the vivarium on 12 hour light and 
12 hour dark period. Mice were fed with special diet chow (20% lactose, 2% calcium 
and 1.25% phosphorus) to maintain phosphorus and calcium homeostasis and 
allowed access to chow and water ad libitum. Heterozygous males and females were 
used for breeding and genotypes were screened by PCR using primers and protocols 
published on the Jackson Laboratory website.  
http://jaxmice.jax.org/protocolsdb/f?p=116:2:0::NO:2:P2_MASTER_PROTOCOL_ID,
P2_JRS_CODE:1160,006133 
MCMV infection of VDR knockout mice 
3-4 month old female mice were infected via intraperitoneal injection of 106 pfu MCMV 
pARK25 virus per animal. At day 4 post-infection, infected mice were sacrificed. 
Spleens were isolated, homogenized and used for plaque assay. 
58 
 
MCMV plaque assays 
105 NIH 3T3 cells were plated into each well of 12 well plates and maintained in 
DMEM supplemented with 10% calf serum, and penicillin and streptomycin as 
described previously. 1 μl or 10μl tissue homogenate was added to each well to 
infect NIH 3T3 for 3 hours in 37℃ 5% CO2. After infection, inocula were removed, 
and CMC/MEM (1:1) mixture was overlaid  on NIH3T3 monolayer. Cells were 
incubated in cell culture incubator for five days to allow plaques to develop. On day 5, 
cells were fixed with methanol, and stained with Giemsa. Plaque numbers were 
quantified using a dissecting microscope. 
General reagents 
Human TGF-β was generously provided by Dr. Thomas Thompson. Anti-HCMV IE 
antibody conjugated to Alexa 88 was purchased from Millipore. Anti-Human CD14 
antibody conjugated to APC was obtained from eBioscience. 
TGF-βtreatment 
THP-1 cells grown as described above were treated with 10 ng/ml TGF-β, 10 ng/ml 
TGF-βcombined with various concentrations of 1,25-dihydroxyvitamin D3, or vehicle 
for designated time periods prior to infection. 
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Results 
Replication of murine cytomegalovirus (MCMV) in VDR knockout BALB/c mice 
Since our results demonstrated that 1,25-dihydroxyvitamin D3 can promote HCMV 
replication in monocytes in vitro, we wished to determine whether 
1,25-dihydroxyvitamin D3 would also affect murine cytomegalovirus (MCMV) 
replication and hypothesized that replication of MCMV might be increased in animal 
models of MCMV infection. We used vitamin D receptor (VDR) knockout mice on the 
Balb/c background to examine this question. Mice were intraperitoneal injected with 
MCMV strain pARK25 at a MOI of 1x106 pfu per animal. At day 4 post-infection, VDR 
knockout mice (-/-), heterozygous (+/-) and wildtype (WT) mice were sacrificed, and 
Figure 11. Murine cytomegalovirus replicates to a similar degree in 
spleens of wildtype and vitamin D receptor knockout mice. Mice were 
infected i.p. with the MCMV pARK25 strain at 106 pfu per animal. At day 4 
post-infection, mice were sacrificed, and spleens were harvested.  Spleen 
homogenates were used to infect NIH 3T3 cells for plaque assay. WT: 
wildtype, +/-: heterozygous mouse, -/-: knockout mouse, n.s.: not 
statistically significant. 
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spleens were isolated, and homogenized. Homogenates were used for plaque assay 
to determine viral titers (Figure 11). 
  The results indicated that infected VDR knockout mice did not display significant 
differences in viral titers in the spleen suggesting that the VDR is not critical for MCMV 
replication in vivo. However, while innate immune response should happen very fast 
after infection (164,165), whether there is a difference in an earlier time-point after 
infection is unknown. In addition, although it is known that vitamin D can regulate 
immunoresponsiveness in both human and mouse(166,167), there are some 
differences in the genes that are regulated by vitamin D when comparing mouse and 
human. For example, in humans cathelicidin (LL-37) is a gene that is well known to be 
regulated by vitamin D with a demonstrable VDR binding site in the promoter region, 
but in mouse, there is no VDR binding site in the promoter area (168). Therefore, it is 
also possible that vitamin D may not have an effect in MCMV replication in murine 
myeloid cells, while having a profound effect on HCMV replication in humans. Further 
studies will be needed to clarify these issues. 
 
The influence of TGF-β  on HCMV replication in 1,25-dihydroxyvitamin D 
differentiated THP-1 cells 
It is known that TGF-β can act synergistically with vitamin D to promote 
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monocyte-macrophage differentiation (47-49). Therefore, we hypothesized that 
TGF-β and vitamin D may function together to synergistically enhance HCMV 
replication in monocytes. We first repeated the experiments regarding the effects of 
TGF-β and 1,25 -dihydroxyvitamin D3 on monocyte differentiation (Figure 12, panel 
A). When THP-1 cells were treated with 1 nM of 1,25 -dihydroxyvitamin D3 alone for 3 
days, CD14 expression is induced by 20 fold, while10 ng/ml TGF-β treatment alone 
induced CD14 expression by 5 fold. TGF-β plus vitamin D caused the strongest CD14 
expression, and when comparing with control THP-1 cells, the CD14 expression was 
Figure 12. TGF-β combined with 1,25-dihydroxy vitamin D3 promotes THP-1 
differentiation and HCMV replication  
(A) THP-1 cells were treated with vehicle (EtOH), TGF-β (10 ng/ml), vitamin D, or 
TGF-β plus vitamin D for 3 days, and CD14 was analyzed by flow cytometry. (B) THP-1 
cells were treated as mentioned in (A), and infected with TB-40 E virus at MOI of 10. 
At day 1 post-infection, cells were harvested, and stained with anti-HCMV IE antibody 
conjugated to Alexa-488. The percentage of IE positive cells was assessed by flow 
cytometry. (C) At day 6 post-infection, 10,000 THP-1 cells/sample were harvested and 
co-cultured with human foreskin fibroblasts for 2 days. After 2 days of co-culture, 
fibroblast monolayers were overlaid with CMC/MEM and incubated for 8 days to 
allow for plaque development. The data represent 3 independent experiments. 
* :p<0.05,  ** :p<0.01, *** : p<0.001 
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increased by almost 38 fold (Figure 12A). These results are consistent with the 
previous observations that TGF-β and vitamin D together can promote increased 
monocyte-macrophage differentiation (47). We then examined whether the 
combination of TGF-β and vitamin D would enhance HCMV gene expression and/or 
lytic replication. TGF-β treatment alone did not increase the percentage of THP-1 cell 
expressing HCMV IE, but vitamin D alone or vitamin D plus TGF-β increased the 
percentage of THP-1 cells expressing HCMV IE (Figure 12B). TGF-β alone or 1 nM 
vitamin D alone did not lead to increases in viral replication in infectious center assays 
but TGF-β plus vitamin D causes a 4 fold increase in viral replication (Figure 12 C).  
It should be noted that we used a more dilute concentration of Vitamin D (1nM) than in 
earlier studies in this chapter (100nM) to assess the influence of TGF- β on Vitamin D 
induced monocyte differentiation and HCMV replication. The results from this 
experiment further supported that the conclusion that the differentiation state of 
THP-1 cells is crucial for triggering HCMV permissive infection. Whether TGF-β plus 
vitamin D can also promote HCMV replication in primary monocytes is still unknown, 
and it will be an interesting future direction for the research.    
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Chapter III 
Pharmacological dissection of US28, M33 
and ORF74 vGPCR signaling pathways 
using the YM-254890 Gαq inhibitor 
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Abstract 
Herpesviruses are ubiquitous in the human population and can establish life-long 
latency in their hosts. The β- and γ-herpesviruses encode viral G protein-coupled 
receptors (vGPCRs) in the viral genomes. vGPCRs are structurally similar to 
chemokine receptors and can modulate and evade host responses presumably to 
facilitate viral survival and dissemination. Human cytomegalovirus encoded US28, 
mouse cytomegalovirus encoded M33, and Kaposi’s sarcoma-associated herpesvirus 
encoded ORF74 vGPCRs all can constitutively trigger Gαq dependent signal 
transduction. Moreover, it is known that US28, M33, and ORF74 can all activate 
NF-κB, CREB, and NFAT, but whether the activation of these downstream signaling 
molecules is Gαq dependent or not is unclear. Because of the potential role that these 
vGPCRs play in viral pathology and chronic diseases and the possibility that these 
vGPCRs could represent novel drug targets, it is important to dissect the signaling 
pathways initiated by vGPCRs using available pharmacological inhibitors. In this 
research, YM-254890, a pharmacological Gαq/11 specific inhibitor was used to 
determine which downstream signaling molecules are Gαq dependent. Using the 
YM-254890 compound, we demonstrate that the HCMV encoded US28 and MCMV 
encoded M33 vGPCRs use a similar mechanism to activate phospholipase C and 
downstream signaling molecules including NFAT, NF-ΚB, and CREB while the KSHV 
encoded ORF74 uses a distinct signal mechanism to activate the same set of signal 
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molecules. Moreover, the YM-254890 effectively blocks US28 triggered signaling in 
HCMV infected cells demonstrating the utility of this compound. Finally, based on 
these results, we conclude YM-254890 is a potent and specific tool that can be more 
fully exploited for exploring the signaling and function of herpesvirus encoded GPCRs 
both in vivo and in vitro.   
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Introduction 
β- and γ- herpesviruses encode G protein-coupled receptors (vGPCR) 
homologs in their genomes (50,51). These vGPCRs contain all of the components of 
a classical GPCR including 7 transmembrane domains, an extracellular amino 
terminus, and an intracellular carboxy terminus and are most structurally similar to 
mammalian chemokine receptor subfamily of GPCRs (51). Cellular chemokine 
receptors control migration of leukocytes to sites of inflammation, control migration of 
hematopoietic cells out of the bone-marrow lymphoid (169,170)and control movement 
of a number of additional cell types (171,172). Published studies have shown that 
unlike cellular chemokine receptors, which respond to specific chemokines, and are 
typically coupled to Gαi/o (173,174), vGPCRs bind promiscuously to multiple 
chemokines, exhibit high levels of constitutive activity and may even be coupled to 
more than one type of G-protein (68,175,176).  
The members of the β- and γ- herpesviruses establish latency following primary 
infection and utilize multiple mechanisms to modulate cellular regulatory pathways 
thus enabling the viruses to maintain this latent state within the host(177-179). The 
herpesvirus vGPCRs are thought to activate cellular signal transduction pathways to 
facilitate the dissemination of the viruses, facilitate viral growth within specific tissue 
sites, and/or control the lytic/latent switch (50,180).  
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US28 is one of four vGPCRs encoded by the β-herpesvirus human 
cytomegalovirus (HCMV) (56). US28 can bind to multiple chemokines including 
MCP-1, RANTES, MIP-1α, and Fractalkine (56). Previous studies have demonstrated 
that US28 can trigger ligand dependent and ligand independent signaling pathways 
(68,181), and it can also function as a chemokine sink to reduce the concentration of 
chemokines surrounding the infected cells (59). However, research has shown that 
US28 deficient HCMV mutants do not show defects in viral replication in human 
foreskin fibroblasts in vitro (182) and more studies will be required to begin to 
ascertain the functional role that this protein plays in viral pathogenesis in vivo and 
identify the cell types in which US28 plays an important role during infection. US28 
has been implicated as an active participant in HCMV associated pathologies such as 
atherosclerosis and glioblastoma (183,184). In this regard, US28 has been shown to 
promote the migration of vascular smooth muscle cells and macrophages and as such 
may play an important role in the initiation of atherosclerosis(57,58). Moreover, US28 
can activate cellular proliferation pathways and induce cellular transformation 
(185-188) suggesting that US28 may facilitate the progression of HCMV associated 
tumors such as glioblastoma (189). HCMV establishes latency in hematopoietic stem 
cells, myeloid progenitor cells, and monocytes (190) and it is interesting that 
expression of US28 can be detected in these cells in both in vivo and in vitro infection 
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models (Chapter IV). The function of US28 in latency remains unknown, but it is 
interesting to speculate that US28 may play a role in the establishment or 
maintenance phases of latency (179). On the other hand, there are studies showing 
that transient expression of US28 can stimulate the promoter of the HCMV 
immediate-early (IE) gene (191,192) suggesting that US28 could participate in HCMV 
reactivation since the expression of IE gene is a critical step for HCMV reactivation 
(193). Based on all those reasons, US28 is an attractive target for therapeutic 
intervention as blocking US28 signaling activity could intervene in aspects of both 
pathogenesis and HCMV related pathology. 
The highly related mouse cytomegalovirus (MCMV) encodes two vGPCRs 
termed M33 and M78(194). M33, like US28, exhibits high levels of constitutive 
signaling activity(195); however ligands for this vGPCR have yet to be identified. 
Published studies by the several laboratories including ours have indicated that M33 
deficient MCMV replicates with wildtype efficiency in vitro but exhibits a severe 
replication defect in the salivary gland in vivo (60,196). The salivary gland is an 
important site of persistent virus replication and can shed infectious virus into the 
saliva for weeks to months following a primary cytomegalovirus infection(197). The 
salivary gland phenotype exhibited by the ∆M33 virus experiments suggest that 
cytomegalovirus vGPCR signaling may have an important role in host-host 
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transmission occurring via the salivary route. Whether US28 plays a similar role in 
HCMV persistent infection in human salivary glands is still elusive, although research 
has shown that insertion of US28 into M33 deficient MCMV genome can partially 
rescue the phenotype in mouse salivary glands(198).  
The Kaposi’s sarcoma-associated herpesvirus (KSHV) encodes one vGPCR 
in its genome termed ORF74 (52). ORF74 binds to multiple chemokines in the IL-8 
family including IL-8 itself and GRO-α (199). ORF74, like US28, can trigger both 
ligand-dependent and ligand-independent signaling pathways(50). ORF74 is 
particularly noted for its ability to drive increased transcription and secretion of 
vascular endothelial growth factor (VEGF) thus promoting angiogenesis(54). Kaposi’s 
sarcoma tumors are highly vascularized (54,55) and thus the angiogeniesis promoting 
effects of ORF74 have classified it as an oncogene in this setting. From a 
pathogenesis perspective, the ORF74 homolog in MHV-68 has been demonstrated to 
affect viral reactivation from latency (53). Therefore, ORF74 appears to be a central 
player in multiple aspects of KSHV pathogenesis and disease. 
Perhaps one common thread that seems to arise when comparing the 
biological activities of the herpesvirus vGPCRs is their abilities to regulate latency and 
persistence and therefore the identification of pharmacological agents targeting 
common aspects of the signaling activities of these molecules may provide novel 
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therapeutics to regulate herpesvirus latency and persistence.  
Based on previous studies, US28, M33, and ORF74 are known to be 
constitutively (e.g. without agonist) coupled to Gαq and capable of activating a similar 
repertoire of downstream signaling molecules including PLC-β, CREB, NF-κB, and 
NFAT(63,66,67,195). In the case of M33, mutational analysis of the NRY G-protein 
coupling motif has indicated that the activation of NF-κB occurs via a G-protein 
independent mechanism(63), but in the case of US28 and ORF74 whether all the 
downstream signaling molecules are Gαq dependent is unknown. Moreover, studies 
designed to address this topic to this point have not utilized Gq inhibitors to explore 
this question. In some previous studies, the overexpression of individual 
heterotrimeric G proteins has been used to determine which G protein complex is 
engaged by the vGPCRs(68,200). However, the possibility that such an approach 
may initiate the cross-talk or aberrant coupling is a distinct possibility. In the current 
study, we explored using a Gαq specific inhibitor to examine the G-protein 
dependency involved in a broad range to signaling pathways kindled by these 
vGPCRs. 
YM-254890 is a Gαq/11 specific pharmacological inhibitor isolated from 
Chromobacterium sp. QS3666 (25). YM-254890 was initially identified as an inhibitor 
of ADP-induced platelet aggregation (201). Subsequently, it was shown that this 
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compound inhibits ADP-induced platelet aggregation via its ability to specifically 
inhibit Gαq/11. YM-254890 is a cyclic depsipeptide that can bind to GDP bound form 
of Gαq and lock it into its inactive form. In light of the activation of multiple signaling 
molecules by the vGPCRs, and the involvement of vGPCRs in the pathology of many 
chronic diseases, it is crucial to not only identify the pathways utilized by the vGPCRs 
to activate downstream signaling pathways, but also to evaluate compounds that 
could be of potential therapeutic value. 
 In this research, YM-254890 was used to determine which downstream 
signaling activities of US28, M33 and ORF74 are Gαq/11-depedent. As expected, 
based on studies of US28 coupling in Gαq deficient MEFs, YM-254890 inhibits US28 
and M33-induced accumulation of 1,4,5 inositol-trisphosphate (IP3) in a dose 
dependent manner, confirming that these cytomegalovirus vGPCRs are coupled to 
PLC-β via a Gq dependent mechanism. Surprisingly YM-254890 does not have an 
inhibitory effect on ORF74-induced IP3 accumulation suggesting that promiscuous 
coupling of ORF74 to Gαi (200) may be responsible for this signaling. For 
downstream signaling molecules, the inhibition of the activation of CREB by US28 
and M33 is YM-254890 dose dependent and coincides with the concentrations 
necessary to block Gαq activity. In contrast both US28 and M33 signaling to NF-κB is 
resistant to YM-254890 indicating that the activation of NF-κB is Gαq/11 independent. 
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This result confirms previous studies regarding M33 and NF-κB activation and 
suggests that both US28 and M33 use a novel G-protein independent mechanism to 
stimulate NF-κB signaling activity.  US28-and M33-induced activation of NFAT is only 
modestly affected by YM-254890 indicating that NFAT like NF-κB likely uses a 
mechanism distinct from Gαq. 
Taken together, these studies highlight the complexity of herpesviral vGPCR 
signaling and demonstrate that while the receptors can clearly be coupled to Gαq to 
activate downstream signaling, there exists multiple pathways emanating from these 
receptors that are likely to mediate all of the biological effects of the vGPCRs. 
However, these studies do demonstrate that several important activities of the 
cytomegalovirus GPCRs are clearly inhibited by the YM-254890 compound and that 
this compound will be useful in functional assays to define critical aspects of vGPCR 
mediated viral pathogenesis. In particular, the ability of YM-254890 to inhibit multiple 
aspects of MCMV-M33 signaling is particularly interesting and will be useful to begin 
to correlate mechanisms of signaling with in vivo biological activities such as viral 
persistence in the salivary gland.   
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Materials and methods 
Cell culture. HEK cells were maintained in DMEM with 4.5 g/L glucose and 
L-glutamine without sodium pyruvate supplemented with 10% fetal bovine serum, and 
penicillin and streptomycin at 37℃ 5% carbon dioxide. Human foreskin fibroblasts 
were cultured in DMEM with 4.5 g/L glucose and L-glutamine without sodium pyruvate 
supplemented with 10% FetalClone III, and penicillin and streptomycin at 37℃ 5% 
carbon dioxide. 
 
Transient transfection. For transient expression of US28, M33 and ORF74 in HEK 
cells, 15 ng of pcDNA3 plasmid containing the indicated vGPCR was co-transfected 
with 250 ng of pcDNA3 vector into HEK cells. 
 
Luciferase assays. 200,000 cells were plated into each well in 12-well plates, and 
cultured overnight before transfection. For stable HEK cell lines, 250 ng pcDNA3, 10 
ng of pFA2CREB, 30 ng pFRLUC, and 15 ng of phRGTK-renilla were used in 
transfection for the assessment of CREB driven luciferase activity. 250 ng pcDNA3, 
15 ng pMHCLUC, and 15 ng phRGTK-renilla were transfected into stable cell lines for 
determining NF-κB induced reporter activity. For NFAT report assays, 250 ng 
pcDNA3, 15 ng pGL3 9xNFATLUC, and 15 ng phRGTK-renilla were transfected. 
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YM-254890 or DMSO (solvent control) was added at the time of transfection. 
YM-254890 was a gift from Astellas Pharma Inc (Ibaraki, Japan).  48 hours after 
transfection, cells were washed with 1X DPBS, and lysed in 200 μl 1X passive cell 
lysis buffer. After 15 minutes incubation at room temperature, 10 μl of cell lysate was 
used for reporter assays. 50 μl luciferase substrate was added to cell lysate and 
luciferase activity was measured by Glomax 20/20 luminometer (Promega). For renilla 
measurement (internal control), 50 μl Stop & Glow reagent was added to the cell 
lysate, and the intensity was determined by Glomax 20/20 luminometer (Promega). 
To assess reporter gene activity, experimental firefly-luciferase readings from control 
cells were divided by the control renilla-luciferase readings from the same cells and 
defined as 1. Fold induction is calculated by dividing the 
firefly-luciferase/renilla-luciferase ratio of cells expressing the various vGPCRs in the 
presence or absence of indicated concentration of YM-254890 by the 
firefly-luciferase/ renilla-luciferase ratio in control cells. 
 
IP3 accumulation assays. 12-well cell culture plates were coated with collagen and 
200,000 HEK cells were plated into each well. 1 µCi of 3H-myoinositol was added to 
each well to label the cells at 37°C and 5% CO2 overnight (16-18 hours). After 
overnight incubation, labelled cells were treated with DMSO or YM-254890 for the 
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indicated times. Fresh serum free DMEM containing 20 mM LiCl was added to each 
well, and the cells were incubated at 37°C and 5% CO2 for 2-3 hours to let signaling 
generated inositol triphosphates to accumulate. After the 2-3 hour incubation, media 
was removed, 1 ml 0.4 M perchloric acid was added to each well, and the cells were 
incubated in the cold room (4℃) for 15 minutes to quench the reactions. 800 μl of 
perchloric acid containing supernatants were added to fresh Eppendorf tubes 
containing 400 μl of neutralizing buffer (0.72M KOH and 0.6M KHCO3). The mixture 
was mixed by vortex and centrifuged at 13,000 rpm for 2 minutes. 50 μl of the 
supernatant was then mixed with 10 ml of scintillation fluid and used as a reference 
for “total labeling” for each sample. 1 ml of the supernatant was added to 3 ml of 
distilled water and passed through freshly prepared Dowex columns (AG1-8X; 
Bio-Rad). The columns were washed 2X with 2X distilled water. Bound IP3 was eluted 
with 4 ml elution buffer (0.1 M formic acid and 1M ammonium formate). After elution, 
10 ml scintillation fluid was added into each sample and counted in a liquid scintillation 
counter (Beckman Coulter). The eluted samples containing IP3 were divided by the 
reference “total labelling” sample to obtain the percent conversion of myo-inositol into 
IP3 for each sample. 
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Infection of foreskin fibroblasts 105 human foreskin fibroblasts were plated into 
individual wells of 12-well cell culture plates one day before infection. Human 
fibroblasts were infected at a MOI of 1 (i.e. 105 PFU of virus per 105 cells). 
Twenty-four hours post-infection, media were aspirated, and replaced with fresh 
media containing 1µCi/ml 3H-myoinositol and either DMSO or YM-254890.  After an 
additional overnight incubation, the cells were used in IP3 accumulation assays as 
described above.  
 
Statistical analysis. Results are presented graphically and represent the mean ± S.E. 
of three or more experiments.  The intensities of bands on immunoblots were 
quantified using Image J software. Statistical analyses were calculated with unpaired 
two-tailed Student’s t tests using GraphPad Prism® 6 software. Differences were 
considered significant at p < 0.05. *, **, and *** represent p < 0.05, p < 0.01, and p < 
0.001, respectively. Nonsignificant changes are denoted by n.s., and represent p > 
0.05. 
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Results 
The Gαq inhibitor YM-254890 blocks IP3 accumulation in cells expressing 
HCMV-US28 or MCMV-M33 but not in cells expressing KSHV-ORF74 
Since HCMV-US28 has been shown to trigger ligand-independent signaling through 
Gαq using several independent methods (67), we first sought to validate the 
YM-254890 compound using HEK cells stably expressing US28. US28 expressing 
cells were treated with increasing concentrations of YM-254890 and assessed for 
phospholipase C β (PLCβ) activity driven by US28 (Figure 13A). The results 
demonstrate that YM-254890 caused a 74% reduction in PLCβ activity at a 
concentration of 1nM and a 90% reduction in PLCβ activity when the concentration of 
YM-254890 was increased to 20 nM. These data indicated that YM-254890 is a 
potent inhibitor of US28 dependent signaling through Gαq and confirm that 
US28-dependent signaling is Gαq specific.  
Based on previous studies(63,67), which demonstrate that MCMV-M33 can 
trigger similar constitutive signaling pathways to that of US28, we hypothesized that 
YM-254890 would also suppress PLCβ activity triggered by M33. To that end, HEK 
cells were transiently transfected with M33 (and with US28 for control purposes) and 
treated with YM-254890 or DMSO vehicle for 24 hours, and PLCβ activity was 
measured as above. As predicted, M33 driven PLCβ activity was totally suppressed 
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when cells were pretreated with 20nM or 100 nM YM-254890 (Figure 13B). Control 
cells transiently  
Figure 13. YM-254890 inhibits US28 and M33 GPCR induced PLC-β signaling. 
(A) Control HEK cells and stable US28 expressing cells were labelled with 1mCi/ml 
3H-myoinositol overnight, and pretreated with indicated concentration for 5 minutes 
before IP3 accumulation assay. IP3 accumulation was measured using standard 
techniques and converted into percent conversion of input 3H-myoinositol.  The data 
represent five independent experiments. (B) HEK cells were transfected with pcDNA3 
(vector), pcDNA3-M33flag, pcDNA3-flagORF74, or pcDNA3-flagUS28. Transfected cells 
were pretreated with indicated concentration of YM-254890 overnight. IP3 
accumulation was measured and converted into percent conversion of input 
3H-myoinositol. The data represent 3 independent experiments. *:p<0.05, **:p<0.01, 
n.s.: not statistically significant. 
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expressing US28 were equally sensitive to YM-254890 confirming the results 
observed with US28 stable cell lines in Figure 13A.  
KSHV-ORF74 is a third member of the herpesvirus vGPCR family and is also 
known to activate a constitutive signaling pathway leading to activation of PLC-β(65). 
In contrast to HCMV-US28 and MCMV-M33 that are encoded by the 
cytomegaloviruses, prototypical members of the β-herpesvirus family, KSHV-ORF74 
is encoded by the Kaposi-sarcoma herpesvirus, a prototypic member of the 
γ2-herpesvirus family (202). Thus, one might expect ORF74 to function in a manner 
somewhat distinct from that of US28 or M33. Previous studies have shown that 
ORF74 can couple to multiple Gα subunits including Gαq. To determine if 
KSHV-ORF74 signaling is sensitive to YM-254890, HEK cells were transiently 
transfected with ORF74, treated with vehicle or YM-254890 and examined for PLC-β 
mediated IP3 accumulation. Interestingly, YM-254890 caused only a modest, but 
statistically significant reduction (31%) of IP3 , even when using the YM-254890 
compound at the higher dose of 100nM (Figure 13B).  Thus, while the YM-254890 
compound is somewhat effective against ORF74, this effect is much weaker than that 
observed for US28 (96% reduction) or M33 (91% reduction) (Figure 13B). This result 
suggests that the PLC-β induced IP3 accumulation triggered by US28 and M33 is 
predominantly (perhaps totally) Gαq dependent while the PLC-β induced IP3 
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accumulation triggered by ORF74 is only partially Gαq dependent and likely to induce 
PLC-β dependent IP3 accumulation using G-proteins other than Gαq, most likely Gαi.  
 
US28 and M33 but not ORF74 use similar molecular mechanisms to activate 
downstream signaling components 
Based on results of our IP3 accumulation assays, we conclude that while US28, M33 
and ORF74 all can stimulate PLC-β activity; US28 and M33 do so by activating Gα
q-dependent signaling while ORF74 does so through a mostly Gαq-independent 
process. In addition to the proximal effector PLC-β, US28, M33 and ORF74 each also 
activate the more distal signaling pathways including the transcription factors CREB 
(cAMP responsive element binding protein), NFAT (Nuclear Factor in activated T-cells) 
and NF-κB (Nuclear Factor kappa light chain binding protein). Therefore, we next 
wished to determine whether these vGPCRs used a Gαq-dependent or 
Gαq-independent signaling mechanism to activate these transcription factors.  We 
again took advantage of the Gαq inhibitor YM-254890 to address this question. 
Luciferase-based reporter gene assays were utilized to measure the activation of 
each of the transcription factors. In US28 expressing cells, YM-254890 treatment 
leads to a dose dependent decrease of CREB- and NFAT-dependent reporter gene 
activity (60% and 52% percent respectively) (Figure 14A). In contrast 
US28-dependent activation of NF-kB was insensitive to the effects of YM-254890 
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(Figure 14A). The effects of YM-254890 on CREB or NF-AT were not as complete as 
that of PLC-β (~60% versus 90%) and at this point we don’t know if this is due to a 
difference in assay sensitivity or if the CREB/NF-AT transcription factor signaling 
might be somewhat independent of Gαq.  In M33 expressing cells, CREB and 
NFAT activity were strongly reduced by 20nM YM-254890 treatment, while NF-ΚB 
activity is unaffected similar to that observed with US28 (Figure 14B). The lack of 
effect of YM-254890 is not unanticipated as previous results from our group has 
demonstrated using Gαq knockout MEFs and M33 mutants that NF-kB signaling 
from M33 occurs via a G-protein independent mechanism. The details underlying 
US28 and M33 mediated NF-κB signaling remain unclear. Lastly, we examined the 
effects of the YM-254890 on ORF74 mediated activation of the same transcription 
factors. Given that our studies had demonstrated that ORF74 signaling through the 
proximal effector PLC-β was mostly independent of Gαq, we felt that we would 
likely see a similar lack of effect of the YM compound of ORF74 signaling to these 
transcription factors. As predicted YM-254890 treatment did not have influence on 
CREAB, NFAT, and NF-ΚB activity even when an excess concentration (100 nM) was 
used in the experiment (Figure 15). While the ORF74 mediated activation of these 
transcription factors is unaffected by the YM-254890 compound, these results do 
provide an important perspective on the activity of this compound as they enable us to 
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have increased confidence that the YM-254890 compound is a specific inhibitor of 
Gαq and M33/US28 signaling pathways rather than be a non-specific toxin to a 
number of pathways. 
In summary, the results demonstrated that CREB and NFAT activated by US28 
and M33 are at least partially Gαq dependent, while NF-ΚB activation by US28 and 
M33 is not modulated by Gαq. In contrast, although ORF74 can also activate CREB, 
NFAT, and NF-ΚB, the activation of these transcription factors by this particular 
vGPCR occurs via a distinct Gαq independent mechanism. It is interesting that while 
both the β- and γ-herpesviruses have acquired GPCR homologs and appear to 
activate a similar set of signaling pathways, the viruses seem to have evolved to 
activate these pathways using distinct mechanisms. 
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Figure 14. YM-254890 inhibits US28 and M33 induced activation of CREB and NFAT 
but not NF-ΚB 
(A) Control HEK cells and US28 expressing cells were transfected with CREB, NFAT, and 
NF-kB reporter plasmids (from left to right). (B) ) Control HEK cells and M33 expressing 
cells were transfected with  CREB, NFAT, and NF-kB reporter plasmids (from left to 
right). Cells were treated with vehicle (DMSO) or the indicated concentrations of 
YM-254890 for 48 hours. Luciferase assays were performed 48 hours after 
transfection. The data represent 3-4 independent experiments performed in 
duplicate. *:p<0.05, **:p<0.01. 
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Figure 15. YM-254890 has no effect on ORF74 induced activation of CREB, NFAT, and 
NF-κB. HEK cells were transfected with the indicated reporter constructs, internal 
renilla control and ORF74. Luciferase reporter assays were performed. Cells were 
treated with vehicle or 100nM YM-254890 at the time of transfection and reporter 
assays were performed at 48 hours post-transfection. The ratio between firefly 
luciferase and renillla-luciferase obtained from vector control transfected cells 
(pcDNA3) was set to 1.  The data represent 3 independent experiments performed in 
duplicate. n.s.: not statistically significant. 
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YM-254890 can abolish US28-induced IP3 accumulation in HCMV infected 
human foreskin fibroblasts 
Since YM-254890 has been shown to have potent inhibitory effects on US28 and M33 
vGPCR signaling in transfected cells, the activity of YM-254890 toward vGPCR 
signaling in infected cells was the next goal of this research. We have previously 
demonstrated that infection of fibroblasts with the clinical isolate HCMV-FIX strongly 
induces PLC-β activity and IP3 accumulation at 48 hours post-infection and that this 
occurs in a US28 dependent fashion as US28 null viruses lack ability to induce PLC-β 
activity (203). We therefore used wildtype and US28-null HCMV-FIX strains and 
analyzed PLC-β activity/IP3 accumulation in cells with or without the YM-254890 
compound. Human foreskin fibroblasts were infected with HCMV-FIX or 
HCMV-FIX∆US28 strain at an MOI of 3, YM-254890 and 3H-myoinositol were added 
at 24 hours post-infection and IP3 accumulation assays were performed at 48 hours 
post-infection to determine whether YM-254890 can inhibits PLCβ in the context of 
infection. While wildtype FIX virus infection caused a dramatic induction of PLCβ 
activity, infection of US28-null FIX virus did not lead to any induction of PLCβ activity, 
confirming our earlier findings that that the infection induced IP3 accumulation is 
derived from a US28 triggered signal (203). When cells infected with wild type virus 
were treated with YM-254890, a dose dependent inhibition of PLCβ activity was 
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observed, indicating that YM-254890 can also inhibit US28 signaling in infected cells 
(Figure 16).  
In summary our data demonstrates that YM-254890 is a specific and potent 
inhibitor of cytomegalovirus vGPCR signaling in both transfection and infection based 
conditions. The YM-254890 compound is a useful reagent as it will allow us to further 
dissect the signaling pathways triggered by the vGPCRs in vitro and might ultimately 
prove to be a novel pharmacological agent that we could use to inhibit vGPCR 
induced pathogenesis in vivo.  
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Figure 16. YM-254890 blocks US28-induced IP3 accumulation in HCMV 
infected human foreskin fibroblasts  
Human foreskin fibroblasts were infected with FIX and FIX-ΔUS28 virus. At 
day 1 post-infection, cells were treated with indicated concentration of 
YM-254890.  IP3 accumulation assays were performed at 48 hours 
post-infection.  The data represent 3 independent experiments performed 
in duplicate. *p < 0.05; ** p <0.01. 
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Discussion 
YM-254890 has been shown to be a potent and specific Gαq specific inhibitor in 
platelets and in various mammalian cells (25,201,204,205), but this compound has 
not been previously used to study viral encoded GPCR signaling. We find that 
YM-254890 can efficiently block PLC-β/IP3 signal transduction induced by the 
cytomegalovirus vGPCRs HCMV-US28 and MCMV-M33, but cannot block PLC-β/IP3 
signaling induced by the Kaposi sarcoma herpesvirus vGPCR KSHV-ORF74. 
Therefore the CMV and KSHV GPCRs appear to use distinct mechanisms to induce 
PLC-β signaling. Our data indicate that pharmacological approaches using 
YM-254890 are viable alternatives to genetically modified animals for the dissection of 
functional effects induced downstream of cytomegalovirus vGPCR mediated Gαq 
signaling in vivo.  
 Our studies indicate that US28, M33, and ORF74 all can also trigger activation of 
the CREB, NFAT, and NF-κB transcription factors, but that the mechanism(s) 
employed by these vGPCRs to activate these transcription factor signaling pathways 
are not the same. Pre-treatment with YM-254890 indicates that US28 and M33 both 
trigger CREB activation through a Gαq-dependent pathway, but that NF-κB activation 
occurs independently of Gαq. In the case of NFAT activation, YM-254890 inhibits 
US28 induced NFAT activation only at high YM-254890 concentrations, while 
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YM-254890 suppresses M33-driven NFAT activation even at low concentrations 
either suggesting that US28 driven NFAT activation is partially Gαq independent or 
that sustained high levels of Gαq signaling is required for NFAT activation. 
Although ORF74 also triggers strong IP3 accumulation, activation of the CREB, 
NFAT, and NF-κB transcription factors are not inhibited by YM-254890, suggesting 
that these signals are not initiated by Gαq. Interestingly, a recently published study 
demonstrated that ORF74 and US28 can activate NFAT through a PLC independent 
pathway (206), thus providing a plausible explanation for our data, which indicates 
that US28 and ORF74 mediated NFAT signaling is less sensitive or insensitive 
respectively to the effects of YM-254890.  
In this study, we also demonstrate that YM-254890 efficiently blocks IP3 
accumulation induced by US28 in infected cells, and find that even overnight 
treatment with YM-254890 does not cause cytotoxicity in infected cells. This is an 
important and notable finding as it was important to demonstrate that in the context of 
the infection, YM-254890 would also function as a specific inhibitor of CMV vGPCR 
signaling.   
YM-254890 was initially isolated from the culture broth of Chromobacterium sp. 
QS3666 by Yamanouchi Pharmaceutical Co., Ltd.(201). This cyclic depsipeptide 
based compound was subsequently demonstrated to inhibit ADP-induced platelet 
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aggregation by blocking the P2Y1 receptor signaling pathway (201). The 
fermentation-related assets of YM-254890 were transferred to Astellas Pharma, Inc. 
and then to Taiho Pharmaceutical Co., Ltd. For unknown reasons, the company with 
the current rights to the compound (Taiho) is not cut currently making the compound 
available to researchers. A related cyclic depsipeptide, FR900359(207) isolated from 
the Japaneese evergreen Ardisia Crenata, was produced for a short time by the 
Institute of Pharmaceutical Biology at the University of Bonn, but is now similarly 
unavailable. However, due to the specificity and potency of the cyclic depsipeptide 
compounds with known Gαq inhibitory activity, there remains significant interest by a 
variety of investigators for these or related compounds. Recently chemists from 
Washington University, St. Louis reported the synthesis of a YM-254890 analogue 
(WU-07047) (208) and showed that this synthetic compound can specifically inhibit 
Gαq signaling although it is not quite as potent as YM-254890. Moreover, with the 
development of methodologies to synthesize this compound, the possibility exists that 
modifications could be made to the synthetic compound thus improving its potency.  
We are currently working with this group to test the ability of the synthetic WU-07047 
compound to inhibit US28 and M33 signaling. 
In conclusion, we find that YM-254890 is a useful and specific Gαq specific 
inhibitor that could be used to study the functional consequences and mechanism(s) 
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of signaling induced by the cytomegalovirus vGPCRs. YM-254890 (or most likely, the 
recently synthesized YM-254890 analogs) will be especially useful in cell types 
refractory to gene silencing approaches or when the need arises to test the function of 
cytomegalovirus vGPCR Gαq signaling in various tissues or in a high throughput 
manner.  
 
 
 
 
 
 
 
 
  
91 
 
Chapter  IV 
The HCMV US28 vGPCR induces potent 
Gαq/PLC-β signaling in THP-1 monocytes 
leading to altered cellular migration and 
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Abstract 
US28 transcripts have been detected in latently infected THP-1 monocytes but US28 
protein expression has not yet been examined in either latently infected THP-1 cells 
or in primary monocytes/macrophages. Moreover, while US28 has been 
demonstrated to be a potent signaling molecule in numerous cellular systems, 
mechanistic information regarding US28 signaling and function in monocytes remains 
unknown. In this study, we show that US28 protein is robustly expressed in latently 
infected THP-1 cells, and that ectopic expression of US28 can constitutively trigger 
Gαq dependent signaling in THP-1 cells. This US28 signaling dramatically blocks 
chemokinesis through a Gαq dependent pathway while simultaneously promoting 
endothelial cell adhesion. It is known that monocytes are important carriers of latent 
HCMV and are believed to play important roles in viral dissemination. Our studies, 
which demonstrate that US28-driven Gαq signaling has profound effects on monocyte 
biology, suggest that US28 driven phenotypic changes in HCMV infected monocytes 
may play important roles in HCMV dissemination and/or pathogenesis. 
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Introduction 
US28 is a HCMV encoded GPCR, which is structurally similar to human CC 
chemokine receptors, most notably, CCR-1 (181). The HCMV genome encodes four 
such GPCRs (US27, US28, UL33 and UL78), and of these four, US28 appears to be 
the most potent signaler and have the most significant phenotypic effects on infected 
cells (50). Although not essential for replication in vitro(182), previous studies have 
shown that US28 can promote migration of vascular smooth muscle cells (79), 
function as a chemokine sink to reduce chemokine availability in the milieu 
surrounding infected cells (59,182), and facilitate cell to cell viral transmission in 
epithelial cells (209). In human foreskin fibroblasts, the US28 protein is expressed 
with early to late phase kinetics (203). In myeloid cells that support the HCMV 
dormant or “latent” phase, US28 transcripts have been demonstrated to be expressed 
either transiently or persistently after infection depending on the cell type used for the 
experiment(27,28,72). Although US28 is thought to be one of a subset of viral genes 
expressed in the latent phase, what role, if any, US28 plays during latency remains 
unknown. In addition, since the presence of transcripts may not necessarily reflect 
protein expression, whether or not US28 protein is expressed and present in latently 
or lytically infected myeloid cells remains an interesting and important open question. 
Previous results from our lab have shown that US28 triggers constitutive 
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signaling by coupling to Gαq in human foreskin fibroblasts, endothelial cells, vascular 
smooth muscle cells, and glioblastoma derived tumor cells (64). In the canonical Gαq 
signaling pathway, Gαq can activate phospholipase C-β to induce inositol 
triphosphate (IP3) accumulation, which leads to the release of calcium from the 
endoplasmic reticulum (ER) and the activation of protein kinases such as Protein 
Kinase C (PKC)(210). In addition to Gαq, other Gα subunits including Gα12, Gα13, 
Gα16, and Gαi have been shown to be involved in US28-dependent constitutive 
and/or ligand-dependent signaling (57,69,176,211). However, whether or not US28 
triggers a similar or distinct set of signaling pathways in monocytes remains 
unexplored. Thereby, in this research we sought to examine whether US28 can trigger 
constitutive signals in a monocytic cell line, and if so, determine what Gα subunit is 
used by US28 to activate signaling. Pharmacological inhibitors have been widely used 
to assess G-protein signaling activity and many such inhibitors are available including 
Pertussis toxin (Gαi inhibitor) (212), YM-254890 (Gαq inhibitor) (25), U-73122 
(phospholipase C inhibitor) (213), and Ro-32-0432 (PKC inhibitor) (214) all of which 
could be used to tease out the signal mechanism(s) used by US28 in monocytes.  
US28 is a seven-membrane spanning protein with an extracellular amino 
terminus and an intracellular carboxy terminal tail (215). US28, like most members of 
the GPCR superfamily contains a “DRY box” motif (aspartate-arginine-tyrosine) 
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located in second intracellular loop at residues 128-130 that is essential for G protein 
coupling (216), and replacement of arginine 129 with alanine (R129A) abolishes G 
protein coupling (217). In addition, amino acids between residues 11 and 16 in the 
amino terminus of US28 are required for ligand binding(175), and deletion of residues 
2 through 16 (ΔN) eliminates all known chemokine binding to US28 (203). US28 
mutants such as US28-R129A and US28-ΔN are useful tools that can be used to 
dissect and analyze the signals, functions, and mechanisms of US28 action within 
cells.  
The monocyte is not only a cell type in which HCMV can establish latency but 
also is believed to play an important role in viral dissemination. Cell migration is a 
crucial factor for viral dissemination, and previous studies have shown that the binding 
of MCP-1 or RANTES to US28 promotes vascular smooth muscle cell migration (79), 
while binding of Fractalkine to US28 modestly enhances macrophage migration in a 
rat macrophage model (58). Thus, it appears that chemokine binding to US28 can 
have distinct effects on cell migration in a cell type dependent fashion. It remains 
possible and unexplored whether or not US28 can also affect monocyte migration, a 
potentially important phenomenon as it is the monocyte rather than the macrophage 
that is the predominant myeloid cell in the blood where virus dissemination would be 
primarily occurring(80). In addition to cellular migration and chemotaxis, monocyte 
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adhesion to the endothelium is another essential element believed to be important for 
HCMV dissemination (218). It is known that HCMV infected monocytes display 
increased monocyte/endothelial cell adhesion(81), but whether US28 can influence 
monocyte adhesion to the endothelium remains unknown.  
In this study, we found that the US28 protein is expressed in HCMV infected 
THP-1 monocytes, and that US28 can constitutively couple to Gαq to activate 
phospholipase C-β (PLC-β). In addition, we demonstrate that the US28 triggered Gαq 
signal inhibits THP-1 chemokinesis (basal cell migration) and promotes adhesion to 
endothelial cells via a GαqPLC-βPKC signaling axis. The results from these 
studies suggest that US28 protein expression and signaling may influence the biology 
of latently infected monocytes thereby facilitating hematogenous dissemination of 
virus. 
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Material and methods 
General reagents. Anti-human CD36 antibodies were purchased from eBioscience. 
Anti-FLAG M2 agarose beads and anti-FLAG M2 antibody conjugated to biotin were 
obtained from Sigma-Aldrich. Streptavidin conjugated to HRP was purchased from 
BD Pharmagen. Anti-UL44 antibody is a gift from John D. Shanley; University of 
Connecticut. 
 
Construction of US28 lentiviral mutant constructs. pcDNA3-US28FLAG, and 
pcDNA3-FLAG US28 R129A were used as templates for construction of US28 
lentivirus expression constructs. Primers for amplification of wildtype US28 
(US28-WT): Forward primer: 
GTTCGGACTAGTGCCACCATGACACCGACGACGCGACCGCG; Reverse primer: 
GTTCGGTCTAGATTACTTGTCATCATCGTCCTTGTAGTC. Primers for amplification 
of amino terminal truncated US28 (US28-∆N): Forward primer: 
GTTCGGACTAGTGCCACCATGGACGATGAAGCGACTCCCTGTGTC; Reverse 
primer is the same as reverse primer for wildtype PCR reaction. Primers for 
amplification of US28 containing an Arg to Ala mutation at amino acids 129 (US28- 
R129A) were the same as for wildtype US28. PCR reactions were performed for 30 
cycles with denaturation at 94°C for 30 seconds, annealing at 55°C for 30 seconds, 
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and extension at 72°C for 1 minute using Phusion High –Fidelity DNA polymerase 
(New England BioLabs Inc.). The fragments were gel purified using GeneJET Gel 
Extraction Kit (Thermo Scientific), and were digested with SpeI and XbaI. Digested 
fragments were inserted into the SpeI and XbaI sites of the pEN-TmiRC3 entry vector 
(provided by Iain Fraser via Addgene). Inserts in pEN vector were transferred to 
pSLIK-Venus (provided by Iain Fraser via Addgene) using the Gateway LR Clonase II 
Enzyme (Invitrogen).  All constructs were verified by DNA sequencing.  
 
Reverse transcription PCR. Infected THP-1 cells or peripheral blood monocytes 
were harvested, and RNA was isolated using RNA-Bee (Tel-Test, Inc.). 1µg of RNA 
was converted to complementary DNA using an iScript cDNA Synthesis Kit (Bio-Rad). 
PCR reactions were performed for 30 cycles with Taq DNA polymerase using similar 
conditions to those described above. Primers for US28 PCR are WEM-116 (forward 
primer) and WEM-178 (reverse primer). 
 
Production of Lentivirus particles for gene transduction 
4 plates of 2x106 293T cells were transfected with 3 µg of pSLIK-Venus lentiviral 
backbone containing US28 and US28 mutants, 1.5 µg of psPAX2, and 0.5 µg of 
pVSVg using a 4:1 ratio of Mirus LT-1 transfection reagent according to the 
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manufacturer’s and cultured in DMEM supplemented with 10% FBS, penicillin and 
streptomycin. 24 hours after transfection, media were removed and cells were fed 
with fresh media. Culture media containing lentiviruses were then harvested at 48 and 
72 hours post transfection. Viruses were concentrated by ultracentrifugation at 25,000 
RPM for 90 minutes at 4°C.  Supernatants were aspirated, and viral pellets were 
resuspended in 2 ml RPMI-1640 with 10% FBS and penicillin/streptomycin. 2ml of 
viral supernatant was used to infect 4x105 THP-1 cells via spin-fection (centrifugation 
at 1000xg for 90 minutes at 37°C). After transduction, THP-1 cells were cultured 
overnight, and media were changed with fresh media in the morning. At day 2 and day 
4 after transduction, THP-1 cells were analyzed by flow cytometry to examine the 
transduction efficiency. 
 
Isolation of peripheral blood monocytes. Peripheral blood mononuclear cells were 
isolated using Ficoll-Paque PLUS as described previously. Once the buffy coat was 
isolated and washed, cells were cultured in serum free RPMI-1640 for an hour to 
allow monocytes to attach to the plate. Then, unattached cells were washed away 
with DPBS. Fresh RPMI-1640 supplemented with 20% FBS, penicillin, and 
streptomycin was used to maintain monocyte culture. 
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Propagation and purification of HCMV virus. The HCMV 
TB40E-mCherry(3XFLAGUS28) virus was generously provided by Dr. Christine O’ 
Connor from the Cleveland Clinic (64,73). This virus was characterized and 
demonstrated to grow with similar kinetics and to similar titers as does HCMV TB40E. 
To propagate virus, HFFs were infected with TB40E viruses at an m.o.i. of 0.04. Viral 
supernatant was harvested at days 9, 11, and 13 post-infection. Cell Culture 
supernatant containing virus was centrifuged at 1800xg for 3 minutes at 21°C to 
remove cellular debris. The clarified supernatant was overlaid on a 20% 
D-sorbitol/1mM MgCl2 cushion and subjected to ultracentrifugation at 24,000 rpm for 
1hr at 21°C. Supernatant was decanted, and the viral pellet was resuspended in 
RPMI-1640 culture media. Viral supernatant was aliquoted and stored at -80°C. 
UV-inactivated virus was processed by shining the viral supernatant with UV in cell 
culture hood for 15-20 minutes. 
 
HCMV infection of THP-1 cells and peripheral blood monocytes. THP-1 cells 
were infected with HCMV TB40E-mCherry (3XFLAGUS28) at MOIs as indicated in 
the figure legends. After the viral supernatant was added, cells were centrifuged at 
21°C and 1000xg for 30 minutes to enhance infectivity. After overnight culture, cells 
were spun down and the inoculums were removed. Cells were incubated in 1X trypsin 
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for 5 minutes to remove attached but un-internalized virions (120). The trypsin 
reactions were neutralized by adding equal volumes of fresh culture media. The 
supernatant is aspirated, and cells were resuspended in fresh culture media. After 
overnight culture, culture media were removed and cells were washed with 1X PBS, 
and fresh media were added to the cells. UV-inactivated virus was processed by 
shining the viral supernatant with UV in cell culture hood for 15-20 minutes. TB-40 E 
mcherry US28 3xflag virus and TB-40E US28 null virus were used to infected 
peripheral blood monocytes with m.o.i. of 10. One day after infection, cells were 
washed with DPBS and resuspended in fresh RPMI-1640 supplemented with 20% 
FBS, penicillin and streptomycin. 
 
Cell culture. Human endothelial cell line HECV was cultured in DMEM (Dulbecco 
Modified Eagle’s Medium) supplemented with 10% FBS, 100 IU/ml penicillin and 100 
µg/ml streptomycin at 37°C in 5% CO2. Cells are passaged every 3 days. THP-1 
monocytic cell line was maintained in RPMI-1640 (Roswell Park Memorial Institute 
Institute-1640) supplemented with 10% FBS, 100 IU/ml penicillin and 100g/ml 
streptomycin at 37°C in 5% CO2. Cells were passaged every 3 days to keep the cell 
density below 106 cells /ml. 
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IP3 accumulation assays. 2X105 cells were plated into each well in 12-well plates in 
inositol free RPMI-1640 (Roswell Park Memorial Institute Institute-1640) 
supplemented with 10% FBS, 100 IU/ml penicillin and 100 µg/ml streptomycin and 2 μ 
Curi of 3H-myoinositol for 24 hours at 37°C in 5% CO2. 1 μg of doxycyclin or vehicle 
was added to each well to induce gene expression for another 24 hours. Cells were 
harvested and washed with serum free RPMI once. THP-1 cells were resuspended in 
1 ml serum free RPMI supplemented with 20 mM LiCl and incubated at 37°C in 5% 
CO2 for 2 hours. Cells were pelleted by centrifugation at 500 x g for 5 minutes. 
Supernatant was removed. Cells were resuspended in 1 ml percholic acid and 
incubated at 4°C for 15 minutes. Cells were pelleted and 800μl of supernatant was 
added to fresh Eppendorf containing 400 μl of neutralizing buffer (0.72M KOH and 
0.6M KHCO3). The mixture was mixed by vortex and centrifuged at 13,000 rpm for 2 
minutes. 50 μl of the supernatant was then mixed with 10 ml of scintillation fluid and 
used as a reference for “total labeling” for each sample. 1 ml of the supernatant was 
added to 3 ml of distilled water and passed through freshly prepared Dowex columns 
(AG1-8X; Bio-Rad). The columns were washed 2X with 2X distilled water. Bound IP3 
was eluted with 4 ml elution buffer (0.1 M formic acid and 1M ammonium formate). 
After elution, 10 ml scintillation fluid was added into each sample and counted in a 
liquid scintillation counter (Beckman Coulter). The eluted samples containing IP3 
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were divided by the reference “total labelling” sample to obtain the percent conversion 
of myo-inositol into IP3 for each sample. 
 
Immunoprecipitation and western bloting. Cells infected with TB-40E mcherry 3X 
flag virus were harvested at indicated days post infection in RIPA buffer. THP-1 
control cells and THP-1 cells expressing US28 and US28 mutants were harvested in 
RIPA buffer. Cell lysate were passed through a 22 G x 1 ½ needle for ten times, and 
centrifuged to remove cell debris. 50 μl of cell lysate was saved as whole cell lysate. 
20 μl of M2-aggarose beads were added to the rest of the cell lysate, and samples 
were incubated at 4°C overnight. M2-agarose beads were pelleted by centrifugation 
and supernatant were aspirated. Agarose beads were washed 3 times with RIPA 
buffer. 50μl of 3X sample buffer was added to each sample, and let the sample stay in 
room temperature for 30 minutes. 20 μl of each immunoprecipitation sample and 
whole cell lysate were used for 10% SDS-PAGE electrophoresis. After 
electrophoresis, proteins were transferred from SDS-PAGE to nitrocellulose through 
semi-dry transfer apparatus. The cellulose membrane was incubated in 5% skim milk 
for 1 hour. Then the membrane was incubated in rabbit polyclonal anti-flag antibody 
(1: 1000 dilution) at 4°C overnight. The membrane was washed 3 times with TBST, 
and was incubated with goat anti-rabbit HRP conjugated secondary antibody (1:2000 
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dilution) for 3 hours. The membrane was washed 3 times with TBST, and subjected to 
antibody detection using the SuperSignal West Pico or Fento chemiluminescent 
substrate (Thermo Scientific). Luminescence emitted from the membranes was 
detected by classic blue autoradiography film BX. Films were developed by Kodak 
min-R mammography processor. 
 
Transwell migration assays.  1.5x105 THP-1 cells were added into each 5 µm pore 
size insert (Costar), and 600 µl of RPMI-1640 culture medium containing MCP-1 (10 
nM) or vehicle was added to bottom chamber. Cells were allowed to migrate for 2 
hours at 37°C, 5% CO2.  Cells migrating to the bottom chamber were collected, and 
resuspended in 200μl RMPI-1640 culture medium. Input cells were also resuspended 
in 200 μl culture medium. The number of cell migrating to the bottom chamber and the 
number of input cells were determined by flow cytometry. The ratio between the cells 
migrating to the bottom chamber and the input cell was converted into percentage.  
  
Monocyte-endothelium adhesion assay. 105 HECV endothelial cells were plated 
into each well in a 12 well plate and cultured overnight. About 500,000 THP-1 cells 
were harvested and plated into each well to co-culture for 1 hour. The suspended cells 
were removed and each well was washed twice 2 times with culture media. Adherent 
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cells were trypsinized to detach them from the plate. Cells were collected and stained 
with anti-human CD36 antibody for an hour. Cells were washed once with DPBS. 
Cells were resuspnded in 200 μl DPBS. Cells from each well were count by flow 
cytometry, and the number of total cells and CD36 positive cells (THP-1) are 
measured by flow cytometry. The number of CD36 positive cells was divided by the 
total number of THP-1 cells put into each well and the ratio was converted to 
percentage. 
 
Collagen binding assay. 24-well plates were coated with 0.25 mg/ml collagen 
dissolved in 0.2% acetic acid/DPBS for 15 minutes. Plates were washed with DPBS 
twice. 5x105 cells were plated into each well and incubated for 1 hour at 37 °C 5% 
CO2. After incubation, each well was washed with culture media twice. Cells adherent 
to plate were trypsinized for 5 minutes, and trypsin was neutralized by adding an 
equal amount (100 µl) of culture medium. The number of cells adherent to the plate 
was counted by flow cytometry. The number of input cell in each well was also 
determined by flow cytometry. The percentage of cells adherent to the plate was 
determined by dividing the number of cells adherent to the plate by the number of the 
input cell in each well. 
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Statistical analysis. Results are presented graphically and represent the mean ± S.E. 
of three or more experiments.  The intensities of bands on immunoblots were 
quantified using Image J software. Statistical analyses were calculated with unpaired 
two-tailed Student’s t tests using GraphPad Prism® 6 software. Differences were 
considered significant at p < 0.05. *, **, and *** represent p < 0.05, p < 0.01, and p < 
0.001, respectively. Nonsignificant changes are denoted by n.s., and represent p > 
0.05. 
 
Results 
Examination of US28 RNA and protein expression in peripheral blood 
monocytes and in the THP-1 monocytic cell line. 
While previous studies have indicated that US28 transcripts can be detected in THP-1 
monocytes and in primary myeloid cells (26-28), it remained unclear if the US28 
protein was indeed expressed in any of these settings. We initiated our studies by first 
infecting THP-1 cells with a recombinant HCMV TB-40E strain containing an epitope 
tagged US28 gene (TB40E-US28 3XFLAG) and re-examined US28 expression by 
RT-PCR. TB-40E is a HCMV strain with enhanced tropism for endothelial and myeloid 
cells (74,77), and compared to laboratory adapted strains such as AD169 and Towne, 
TB-40E has a more complete complement of viral genes including genes in the ULb’ 
region of the viral genome (76). Infected cells were harvested at various time points 
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post-infection, and RNA was isolated for use in RT-PCR. US28 transcripts were 
detected from 1-8 days post-infection in THP-1 cells (Figure 17A). We also examined 
US28 mRNA levels in peripheral blood monocytes derived by briefly attaching PBMCs 
to plastic and similarly find that US28 mRNA is expressed in these cells, confirming 
that US28 is transcribed in HCMV infected monocytes (Figure 17B). 
 
 
 
 
 
 
 
 
We the sought to examine whether US28 protein is expressed in HCMV infected 
THP-1 cells. To address this point we infected THP-1 cells with wildtype and 
UV-inactivated HCMV strain TB40E-US28 3X FLAG. Since UV-inactivated virus 
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Figure 17. US28 RNA is expressed in infected THP-1 cells and in peripheral blood 
derived monocytes  
(A) THP-1 cells were infected with TB-40E virus or TB-40E US28-null virus at a MOI of 
10. Cells were harvested at day1,2, 4 , 6,8 and 10 post-infection. RNA samples were 
converted into cDNA by reverse transcription. PCR was then performed to analyze 
the expression of HCMV immediate-early genes (IE), US28 (US28) and cellular actin 
as an internal control (actin). (B) Peripheral blood monocytes were isolated and 
infected with TB-40E virus. Infected cells were harvested at days 2, 6, and 8 post 
infection. RNA samples were converted into cDNA by reverse transcription and PCR 
was then performed to analyze gene expression as described above. M: mock 
infection, d.p.i: day post infection. 
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infects cells but does not initiate viral gene expression, it serves as an appropriate 
control to tell us whether US28 protein is present in infected THP-1 cells and 
determine whether this US28 protein is the result of de novo protein synthesis or 
delivered into the cell by infecting viral particle. This latter part of the experiment was 
included in our studies as several groups have proposed that US28 present in the 
viral particles could be inserted into the plasma membrane of the infected cells and 
initiate signaling beneficial to viral replication (219,220). FLAG-tagged US28 protein 
was immunoprecipitated with anti-FLAG M2 affinity gel and analyzed by western 
blotting using biotinylated anti-FLAG M2 antibodies. Our results demonstrate that 
US28 protein is detectable in the THP-1 cells infected with live but not UV-inactivated 
virus. US28 protein expression is delayed somewhat relative to immediate early 
IE1/IE2 proteins but is clearly detectable at 2 and 4 days post-infection virus (Figure 
18). Interestingly, consistent with the observation that THP-1 cells do not support 
efficient lytic replication (136,221), the delayed-early UL44 protein is not detectable in 
this experiment. These results indicated that US28 protein is expressed in 
non-permissively infected THP-1 cells and the presence of US28 protein is through de 
novo protein synthesis rather than being delivered by the infecting virus particle. 
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US28 triggers constitutive Gαq dependent signaling pathways in THP-1 
monocytes 
While several previous studies have shown that US28 can constitutively activate Gαq 
and induce PLC-β dependent IP3 accumulation in fibroblasts, smooth muscle cells, 
and endothelial cells (64,203), whether US28 can trigger constitutive signaling in 
myeloid cells such as monocytes remains unknown. In addition, due to the low levels 
of US28 protein expressed during latent infection and the possibility that unknown 
feedback desensitization pathways could affect US28 signaling in the context of a 
latent infection, we developed an inducible protein expression system to examine 
US28 triggered signaling in THP-1 monocytes. 
Our approach involved the introduction of a lentivirus, pSLIK-VENUS, carrying 
Figure 18. US28 protein is expressed in infected THP-1 cells  
THP-1 cells were infected with TB-40E virus or UV-inactivated virus at MOI of 10. 
Cells were harvested at days 1, 2, and 4 post-infection.  Whole cell lysates were 
analyzed by western blot to examine HCMV immediate early (IE) protein, UL44, and 
actin (internal control). Immunoprecipitation followed by western blotting with 
anti-flag antibodies were performed to analyze US28 protein expression. d.p.i: day 
post infection. 
Mock 1 2 4 1 2 4 (d.p.i.)
TB40E
UV-inactivated 
TB40E
IE
Anti-flag (US28)
actin
UL44
IP: Anti-flag
Blot: Anti-flag
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doxycycline/tetracycline inducible US28 expression cassettes into THP-1 cells. 
Immunoprecipitation and western blot techniques (described above) were then used 
to confirm US28 expression. Using this system, we find that US28 protein is tightly 
repressed in the absence of doxycycline (DOX), but robustly induced within 24 hours 
after addition of DOX to the media (Figure 19). 
 
 
 
 
 
 
 
 
This newly developed, tightly regulatable myeloid-specific US28 expression system 
provides a robust model to explore US28 signaling as it affords us with the ability to 
direct US28 expression only when desirable and alleviates any problems that could 
be attributed to chronic long-term expression of this highly active viral protein.  
To examine the effects of US28 on Gαq/PLC-β driven IP3 accumulation, THP-1 
cells were labeled with 3H-myoinisitol for 48 hours, and US28 expression was induced 
Figure 19. Expression of US28 and US28 mutant proteins in stably transduced THP-1 cells.  
THP-1 cells were transduced with Tet-regulatable pSLIK based lentivruses and sorted on 
the basis of expression of the Venus marker protein. Sorted cells were treated with 1μg/ml 
of doxycycline for 24 hours to induce US28 expression. Immunoprecipitation and western 
blot with anti-flag antibody were used to detect US28 and mutant protein expression. 
Whole cell lysates were analyzed by western blot to detect actin expression.   
Dox - - - -+ + + +
THP-1
actin
anti-Flag (US28)
IP: Anti-flag
Blot: Anti-flag
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with 1µg/ml DOX for the final 24 hours of the labeling protocol. The results of IP3 
accumulation assays demonstrated that US28 causes a 3-fold increase in IP3 
accumulation compared to control THP-1 cells or US28 cells without DOX (Figure 20). 
Since IP3 accumulation is an indicator of the activated of phospholipase C-β(222), a 
downstream effector of Gαq, these result suggested that US28 can constitutively 
activate Gαq in THP-1 cells. To verify that the IP3 signaling is triggered by US28 
coupling to G proteins, we used the US28 DRY box mutant US28 R129A, which 
cannot couple to heterotrimeric G proteins (217). Expression of US28 R129A was 
confirmed by immunoprecipitation and western blot and shown to be similar to that of 
wildtype US28 (Figure 19). While the protein expression levels of US28 R129A are 
similar to that of wildtype US28 after doxycycline treatment, IP3 signaling is not 
triggered by US28 R129A mutant (Figure 20), indicating that the US28-driven IP3 
accumulation is indeed G protein-dependent.  
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Since it is known that US28 can bind to multiple chemokines(175,215), it is possible 
that chemokines secreted by monocytes such as MCP-1(223,224) could be binding to 
US28 and activating signaling in an autocrine fashion. Therefore the US28 N-terminal 
truncated mutant (DN US28), which lacks amino acid 2 to 16 and cannot bind to 
chemokines(203) was used to determine whether the IP3 accumulation induced by 
US28 is occurring a constitutive or ligand dependent signaling process. The 
expression of DN US28 was also verified by immunoprecipitation and western blot 
(Figure 19), and the expression levels were found to be similar to both US28 wildtype 
and US28 R129A. THP-1 cells expressing DN US28 showed a significant induction of 
Figure 20. US28 induces IP3 accumulation in THP-1 cells  
Transduced THP-1 cells were labeled with 3H-myoinositol overnight and then US28 
expression was induced with 1 µg/ml of doxycycline or vehicle (H2O) for an 
additional 24 hours. Assays were performed as described previously. The 
percentage conversion of 3H-myoinositol into 3H-IP3 conversion was calculated by 
dividing inositol phosphates eluted from anion exchange columns by total label 
counts.  The graph represented four independent experiments. Unpaired Student 
t tests were used to examine the data for statistical significance. DN: N-terminal 
deletion US28, R129A: US28 with DRY box mutation**:p<0.01, *: p<0.05, n.s.: not 
statistically significant. 
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IP3 accumulation when compared to control cells or DN US28 cells without DOX, 
indicating that the US28 signaling we observe is due to constitutive signaling activity 
and unlikely to involve autocrine signaling mediated by secreted chemokines (Figure 
20). Taken together, the data obtained from these experiments indicated that US28 
can constitutively couple to heterotrimeric G proteins to kindle signal transduction in 
monocytes. 
While the cellular chemokine receptors mostly highly similar to US28 are 
classically coupled to Gαi (173,174), much of the previous work with US28 has 
demonstrated that it is constitutively coupled to Gαq. Therefore, to determine which 
Gα subunit is utilized by US28 for this constitutive signaling in monocytes, we 
re-examined US28 induced IP3 accumulation using pharmacological inhibitors of the 
relevant G-proteins. In particular, Gαi and Gαq inhibitors were used along with a 
PLC-specific inhibitor to examine this question. YM-254890, a Gαq specific 
inhibitor(25), suppressed the IP3 signaling induced by US28, as did U-73122, a PLC 
inhibitor (Figure 21)(213). However, pertussis toxin, a Gαi inhibitor(212), had no effect 
on IP3 accumulation activated by US28 indicating that in the case of US28, Gαq and 
not Gαi is the specific G-protein responsible for activating this signaling (Figure 21). In 
summary, using a combination of US28 mutants and pharmacological inhibitors, we 
demonstrate that US28 can constitutively trigger Gαq-dependent signaling 
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transduction in monocytes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
US28 inhibits THP-1 monocyte chemokinesis  
While US28 protein is expressed in HCMV infected THP-1 monocytes, the 
function that US28 plays in this cell type remains unknown. Our heterologous 
expression experiments indicate that US28 is a robust activator of G-protein 
dependent signaling suggesting that this signaling activity may impart significant 
phenotypic changes to these cells. Since it has been reported that US28 affects 
migration of smooth muscle cells and rat macrophages(58,79), we wished to explore 
Figure 21. Inhibition of US28 signals by Gαq and PLCβ inhibitors Transduced 
THP-1 cells were labeled with 3H-myoinositol 1 day before induction, and 
treated with 1 µg/ml of doxycycline or vehicle (H2O) for 24 hours. THP-1 cells 
were pretreated with inhibitors of Gαq (YM-254890, 100 nM), PLCβ (U73122, 2 
µM ), or Gαi (pertussis toxin, 200nM) for 30 minutes before IP3 assays. Percent 
conversion of IP3 was calculated as described previously. The graph represents 
three independent experiments performed in duplicate. Unpaired Student T 
tests were used to analyze the data. YM: YM-254890, PTX: pertussis toxin, ***: 
p=0.001,**:p<0.01, *: p<0.05, n.s.: not statistically significant. 
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what effect, if any, US28 signaling has on migration of monocytes using our system. 
To explore this question, Boyden-chamber transwell migration assays were employed. 
In these assays spontaneous movement of cells across the transwell membrane into 
the bottom chamber is defined as chemo- “kinesis” while chemokine dependent 
movement of cells into the bottom chamber is defined as chemo-“taxis”. Interestingly, 
when US28 expression is induced overnight following addition of DOX, this severely 
inhibited spontaneous chemokinesis of THP-1 monocytes (Figure 22A). In other 
words, THP-1 monocytes expressing US28 are much less motile than the control cells 
Figure 22. US28 derived inhibitory effects on THP-1 chemokinesis and chemotaxis.  
(A) Transduced THP-1 cells were treated with 1 µg/ml of doxycycline or vehicle (H2O) for 24 
hours to induce US28 expression. Transwell assays were performed for 2 hours in the absence 
of chemokines. (B) Transduced THP-1 cells were treated with 1 µg/ml of doxycycline or 
vehicle (H2O) for 24 hours to induce US28 expression. Transwell assays were performed in the 
presence of 10 nM of the CC chemokine monocyte chemotaxis protein 1 (MCP-1). Numbers 
of input cells and cells migrating to the bottom chamber were determined by flow cytometry. 
The ratios between cells in the bottom chamber and input cells were converted into percent 
migration. The graphs represented four independent experiments. Unpaired Student t test 
was used to analyze the data. ***: p<0.0001, *: p<0.05, n.s.: not statistically significant. 
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lacking US28 expression. 
We then tested the effect of the monocyte chemotactic protein MCP-1 on THP-1 
monocyte migration. In this experimental setting the effects of MCP-1 could be two 
fold. First, it is a potent chemotactic agent towards monocytes and second, it has the 
potential to bind US28 and alter its signaling properties. MCP-1 induced chemotaxis 
to the bottom chamber was only modestly decreased in cells expressing US28 (Figrue 
22B) indicating that while US28 expression paralyzes basal cell migration 
(chemokinesis), they retain the ability to migrate towards chemoattractants 
suggesting that US28 expression may reprogram the monocytes to migrate 
specifically to a subset of chemokines. 
Our results indicated that US28 can inhibit basal migration (chemokinesis) and 
possibly de-regulate chemokine-driven migration (chemotaxis) of THP-1 cells. We 
wished to further explore this phenomenon using our signaling dead (R129A) and 
chemokine-binding defective (DN) US28 mutants. Based on our signaling studies, we 
know that both US28 and DN US28 can initiate constitutive GαqIP3 signaling, while 
US28 R129A cannot. Therefore, using these mutants we can determine whether the 
inhibitory effect of US28 on cell migration is signaling dependent and/or chemokine 
binding dependent. The effect of US28 on inhibiting chemokinesis is lost in cells 
expressing US28 R129A but not in cells expressing DN US28, indicating that US28 
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derived signaling is responsible for the inhibition of cell migration (Figures 22 A and 
B).  
Based on our findings that constitutive US28 signaling inhibits chemokinesis, we 
next wished to investigate the molecular details of the signaling pathway involved in 
inhibition of chemokinesis. In the monocytes, our earlier studies have established that 
US28 induces a GαqPLC-βIP3 signaling pathway so we focused our studies on 
this pathway. In these experiments, since US28 inhibits basal cellular migration, we 
would predict that inhibiting key components of this signaling pathway would restore 
basal migration (i.e rescue the effects of US28). Pre-treatment of US28 expressing  
Figure 23. US28 induced Gαq signaling is required for inhibition of THP-1 chemokinesis  
Transduced THP-1 cells were treated with 1 µg/ml of doxycycline or vehicle (H2O) for 24 
hours to induce US28 expression and cells were treated with Gαq inhibitor (YM-254890), 
PKC inhibitor (Ro-32-0432), or vehicle (DMSO). Transwell assays were performed for 2 
hours.  Numbers of input cells and cells migrating to the bottom chamber were 
determined by flow cytometry. The ratios between cells in the bottom chamber and 
input cells were converted into percent migration. The graph represented four 
independent experiments. Unpaired Student t test was used to analyze the data. **: 
p<0.01, *: p<0.05, n.s.: not statistically significant. 
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 cells with the Gaαq inhibitor, YM-254890 led to a significant recovery in cell migration, 
indicating that US28 signaling through Gαq plays an important role in down-regulation 
of THP-1 migration (Figure 23). 
Protein kinase C (PKC) is known to be a downstream kinase in the Gαq signaling 
pathway(225,226), and to determine whether US28 inhibits THP-1 through PKC, PKC 
inhibitor RO-32-0432 (214) was used to treat US28 expressing cells. RO-32-0432 
treatment did not rescue the inhibitory effect of US28 on cell migration (Figure 23). 
Therefore, PKC is not involved in modulation of US28 induced inhibition of THP-1 
migration.  
 
US28 promotes THP-1 monocyte adhesion to endothelial cells  
Monocytes, a cell type in which HCMV establishes latency, typically circulate 
throughout the blood system, and when stimulated by inflammatory signals, they 
extravasate across the endothelial lining into surrounding tissues where they 
differentiate into macrophages (80,227). In the case of HCMV infected monocytes, as 
monocytemacrophage differentiation proceeds during and after adhesion to the 
endothelial cell layer (81,91,95), HCMV is thought to transition from a latent stage into 
a lytic one. Since US28 has a dramatic effect on monocyte migration in our THP-1 
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system, we hypothesized that US28 might also affect adhesion of the THP-1 cells to 
an endothelial monolayer. THP-1 cells induced to express US28 via DOX addition 
were added to endothelial cell monolayers and allowed to adhere for a time course 
between 5 and 60 minutes. We chose this time course based on published studies by 
other groups using THP-1 cells as a model for endothelial adhesion (228-230). At 
each time point, non-adhered THP-1 cells were removed from the endothelial 
monolayer by washing twice with culture media. Monolayers containing endothelial 
cells and adhered THP-1 cells were harvested and stained with the CD36, which is 
expressed on THP-1 cells but not on the underlying endothelial monolayer. US28 
expressing cells showed a significant increase in endothelium adhesion at all time 
points tested (Figure 24). 
Cells expressing either wildtype US28 or the DN US28 mutant exhibited a 7-10% 
increase in cell adhesion at 60 minutes, while cells expressing the US28 R129A 
mutant do not demonstrate any increase in cell adhesion (Figure 25). Based on the 
data with US28 mutants, these data again imply that US28 derived signaling may play 
an active role in facilitating cell adhesion to endothelial cells (Figure 25). 
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 Figure 24. US28 promotes monocyte-endothelial adhesion.  
Transduced THP-1 cells were treated with doxycycline (1µg/ml) or vehicle 
(water) for 24 hours to induce US28 expression. Cells were then co-cultured 
with and HECV cell endothelial monolayer for indicated times. Unattached 
cells were removed by washing with media. The number of attached cells and 
input cells were counted by flow cytometry. The data represent 3 
independent experiments performed in duplicate. **  : p<0.01, *** : 
p<0.001 
 
Figure 25. US28 induced constitutive signaling regulates monocyte-endothelium 
adhesion. 
Transduced THP-1 cells were treated with 1 µg/ml of doxycycline or vehicle (H2O) for 
25 hours to induce US28 expression. 5x105 THP-1 cells were co-cultured with HECV 
cells for one hour, and unattached cells were washed away with media. Numbers of 
input cells and cells attaching to HECV cells were determined by flow cytometry. The 
ratios between cells attaching to HECV cells and input cells were converted into a 
percentage. The graph represented eight independent experiments. Unpaired Student 
t test was used to analyze the data. ***: p<0.0001, *: p<0.05, n.s.: not statistically 
significant. 
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 It is especially intriguing that the US28 DN mutant induced monocyte adhesion 
similarly to that of US28 WT. US28 has been shown to be able to bind to 
fractalkine(231), an adhesion molecule which can be expressed by endothelial 
cells(232,233). Therefore, it was possible that US28-mediated monocyte adhesion to 
endothelial cells would be occurring through a mechanism involving binding of US28 
to fractalkine present on the endothelial cell surface. However, our results show that 
this is not the mechanism that US28 uses to promote monocyte-endothelial cell 
adhesion because US28 and DN US28 can promote monocyte adherence to 
endothelial cells while US28 R129A does not. Therefore, based on these data we 
conclude that ligand binding is not involved in the US28-mediated 
monocyte/endothelium adhesion observed in our studies. Rather, the data support the 
notion that US28 signaling is an important factor in this process. 
To explore the nature of the constitutive US28-based signaling involved in 
regulation of monocyte-endothelial adhesion, we investigated the effects of the Gαq 
and PKC inhibitors that we used previously in signaling and chemotaxis assays. The 
Gαq specific inhibitor YM-254890 and PKC inhibitor Ro-32-0432 were both validated  
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Figure 26. US28 induced activation of Gαq and PKC promotes monocyte-endothelium 
adhesion. 
Transduced THP-1 cells were treated with 1 µg/ml of doxycycline or vehicle (H2O) for 24 
hours to induce US28 expression. Induced cells were then pretreated with inhibitors of 
Gαq (YM-254890, 100 nM), PKC (Ro-32-0432, 5 µM), or vehicle for an hour. 5x105 THP-1 
cells were co-cultured with HECV endothelial cells for one hour and unattached cells were 
washed away with media. Numbers of input cells and cells attaching to HECV cells were 
determined by flow cytometry. The ratios between cells attaching to HECV cells and input 
cells were converted into a percentage. The graph represents four independent 
experiments. Unpaired Student t tests were used to analyze the data. **: p<0.01, ***: 
p<0.0001, n.s.: not statistically significant. 
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prior to being used in these experiments (Figures 21 and 23). Cells were treated with 
DOX overnight to induce US28 expression and then treated with inhibitors for 1 hour 
before being overlaid onto the endothelial cells. Both inhibitors abolished the US28 
induced increase in cell adhesion, showing that US28 induced Gαq dependent PKC 
activation is involved in regulation of monocyte-endothelium adhesion (Figure 26). 
 
 
Figure 27. US28 induced activation of Gαq and PKC promotes THP-1 adhesion to 
collagen. 
Transduced THP-1 cells were treated with 1 µg/ml of doxycycline or vehicle (H2O) 
overnight to induce US28 expression. Cells were pretreated with inhibitors of Gαq 
(YM-254890, 100 nM), PKC (Ro-32-0432, 5 μM), or vehicle for one hour prior to being 
overlayed onto HECV endothelial cells. 5x105 THP-1 cells were added to wells of a 24 
well-plate that had been pre-coated with collagen. Cells were allowed to adhere for 
one hour, and unattached cells were washed away with media. Numbers of input cells 
and attached cells were determined by flow cytometry. The ratios between cells 
attaching to the plate and input cells were converted into percentage. The graph 
represents 3 independent experiments performed in duplicate. Unpaired Student T 
tests were used to analyze the data. * : p<0.05, **: p<0.01.  
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Although in the monocyte-endothelium adhesion assay, the media used for the 
assays does not contain inhibitors, it is possible that trace levels of the inhibitors could 
be carried over thereby influencing monocyte-endothelial adhesion by modulating the 
phenotype of the endothelial cell but not the monocyte. To address this issue we 
examined THP-1 monocyte adhesion to plastic culture dishes that were coated with 
collagen. Interestingly, US28 also promoted the ability of THP-1 monocytes to adhere 
to the collagen coated plastic (Figure 27). Therefore, we conclude that the increased 
adherence of THP-1 monocytes is due to a direct effect of US28 signaling on the 
phenotype of the THP-1 monocytes. Since our data indicated that pharmacological 
inhibition of Gα q and PKC signaling pathways blocked monocyte/endothelial 
adhesion (Figure 26) we predicted that inhibition of these pathways would similarly 
block direct monocyte adhesion to collagen.  As hypothesized inhibition of Gαq 
(with YM-254890) and PKC (with Ro-32-0432) caused significant decreases in US28 
induced collagen binding confirming that both Gαq and PKC are essential for US28 
induced c ell adhesion phenotype (Figure 27). 
In summary, we demonstrate that US28 signaling modulates both monocyte 
migration and monocyte-endothelial adhesion. Moreover, both of these processes 
involved classical G-protein signaling via the Gαq pathway.  
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Discussion 
In this research, we demonstrate that US28 protein is expressed in latently 
infected THP-1 cells, and that ectopic expression of US28 in THP-1 cells leads to 
constitutive activation of Gαq signaling, which leads to the inhibition of cellular 
chemokinesis and induction of THP-1/endothelial cell adhesion. Our results provide 
novel insights into the function and signaling of US28 in a cell type that can serve as a 
reservoir for HCMV latency. Since monocyte migration and adhesion to endothelial 
cells are cellular properties important for viral dissemination (80), our results raise the 
possibility that US28 may play an essential role in HCMV dissemination. In murine 
cytomegalovirus (MCMV) studies, it has been shown MCMV M33-null virus has a 
defect in viral dissemination as it fails to grow in the salivary gland and a US28 
rescued virus showed partially restoration in salivary gland growth (198), supporting 
the hypothesis that US28 can influence viral dissemination.  
Our studies primarily use inducible US28 expressing THP-1 cells to explore the 
functional activities and signaling pathways induced by US28 expression because 
only 5-8% of monocytes or THP-1 cells express HCMV genes after infection (Chapter 
2) and it is difficult to examine signaling and function when the uninfected cells 
outnumber the infected cells by such a large margin. In addition, as HCMV encodes 
over 200 gene products, many of which influence cell signaling and could thereby 
mask the effects of US28, it is important to first examine US28 function in isolation in 
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specific cell types and then to revisit interesting questions at a later point in the 
context of infection. Due to these limitations, we chose to use an inducible ectopic 
expression system to investigate the signal and function of US28 in THP-1 cells. Once 
the effects of US28 in monocytes and THP-1 cells is determined, pure infected cell 
populations could be established by flow cytometry or drug selection and used to 
confirm US28 function and signaling in the context of infection context. We are 
currently performing experiments in primary monocytes to examine US28 protein 
expression and examining whether US28 inhibits chemokinesis and promotes cell 
adhesion in primary cells are future directions for our studies.  
We provide evidence that US28 can inhibit monocyte migration in a 
Gαq-dependent, but PKC-independent fashion. Further research is needed to explore 
the downstream signal molecules that regulate the US28 induced down-regulation of 
monocyte migration. One interesting potential avenue could be whether or not US28 
alters basal cytoskeleton function in these cells. Gαq is linked to Rho signaling via 
p63Rho-GEF (234) and would be interesting to explore a link between constitutively 
active Gαq and the cytoskeleton (235). The concept of “constitutive” signaling 
remains an enigma regarding downstream processing and it is interesting to 
speculate that chronic activation of p63Rho-GEF could actually have a deleterious 
effect on cytoskeletal regulation.  
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We also provide evidence that US28 promotes monocyte/endothelial adhesion via 
the activation of a GαqPLC-βPKC pathway. The mechanism of US28 promoted 
adhesion is somewhat surprising given that US28 can bind cell surface ligands such 
as fractalkine(231), but it is clear from our mutant studies that the amino-terminus of 
US28 is not required for this activity and that pharmacological inhibition of monocyte 
signaling pathways abolishes this activity. The target(s) downstream of PKC in this 
process have not yet been identified yet. One possible candidate PKC target is α4β1 
integrin. Previous studies have demonstrated that PLC-β activation leads to an 
inside-out signal for α4β1 integrin activation (236) which causes increased adhesion 
to VCAM-1 and fibronectin found on endothelial cells (228). 
HCMV infection has frequently been reported as a potential co-factor in the 
promotion of atherosclerosis (83,162,237). Several groups have speculated that 
US28 could impact the progression of atherosclerosis via the stimulation of smooth 
muscle cell migration (79,238,239). However, many studies have implied that 
monocyte-endothelium adhesion is a crucial factor for atherosclerosis (240-242) and 
our results suggest that US28 could have an additional function in the development or 
promotion of atherosclerosis (184) by promoting monocyte adhesion to the 
endothelium adjacent to the developing plaque. Future research and the development 
of appropriate animal models will be needed to verify whether US28 indeed can affect 
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atherosclerosis.  
   The ability of US28 to activate Protein kinase C may have broad implications 
beyond the scope of the current study. PKC is known to affect the differentiation of 
myeloid cells(243,244), a process clearly central to the HCMV latentlytic switch(19). 
We have not observed any significant effect of US28 on myeloid maturation and 
differentiation in the THP-1 model (data not shown). However, it is possible that US28 
signaling through PKC may have profound effects on the differentiation of myeloid 
progenitor cells and influence progression of HCMV into the lytic phase. Cord-blood 
derived CD34+ hematopoietic progenitors (HPCs) (72) and the Kasumi-3 cell line 
(120) have both been appropriate for HCMV latency studies, and it would be intriguing 
to determine whether US28 signaling through PKC can influence HPC and/or 
Kasumi-3 differentiation. 
   In summary, in these studies we demonstrate that US28 protein is expressed in 
non-permissively infected myeloid cells and has the potential to regulate monocyte 
migration and adhesion. Therefore, we speculate that US28 not only has important 
functions in the permissive phase but also may play a crucial role in viral latency in 
myeloid cells and progenitors, establishing US28 as an important target for novel 
therapeutics to combat HCMV pathogenesis and disease. 
 
129 
 
Chapter V. 
Discussion and future directions 
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   In Chapter II of this thesis, we demonstrate that vitamin D (1,25-dihydroxyvitamin 
D3) treatment of THP-1 cells or primary monocytes can lead to 
maturation/differentiation of monocytes and support permissive infection of HCMV. 
One of the future directions that we want to investigate is to assess the influence of 
vitamin D treatment on HCMV replication in hematopoietic progenitor cells. Vitamin D 
treatment has been reported to promote monocyte-macrophage lineage commitment 
in hematopoietic progenitor cells (150). Therefore, we hypothesize that vitamin D 
treated hematopoietic progenitor cell could have an increased percentage of cells that 
are permissive for HCMV lytic replication due to an increased number of 
hematopoietic progenitor cells committed to the monocyte-macrophage lineage.  
In addition, the effect of vitamin D on HCMV reactivation is another area of 
interest that has not been explored. To investigate this point, hematopoietic progenitor 
cells will be infected with HCMV using conditions that favor establishment of latency. 
Once the cells have established a latent infection, they will be treated with vitamin D 
for two weeks. Based on published results, two weeks has been established as an 
appropriate time point to promote an increased commitment to the 
monocyte-macrophage lineage (150). Since it is known that HCMV reactivates from 
latency when monocyte differentiates into macrophage or mature dendritic cell (245), 
vitamin D may increase the likelihood that HCMV reactivation will occur by 
131 
 
augmenting the number of cells committed to the monocyte-macrophage lineage. 
Since Vitamin D has such a profound effect on HCMV replication in human 
monocytes, we chose to use the murine cytomegalovirus (MCMV) system to ask 
whether Vitamin D and the Vitamin D receptor (VDR) would similarly affect MCMV 
replication in an in vivo model. Unfortunately, our preliminary data using wildtype and 
VDR-/- mice did not reveal a significant difference in MCMV titers in the spleen at day 
4 post-infection. However viral replication parameters during earlier stages of infection 
(days 1-3) during which innate immunity plays a more central role in controlling CMV 
infection (164,165) has not been investigated. Given that the action of monocytes and 
other innate immune cells towards CMV infection can happen within 2 days of the 
initial infection, it would be intriguing to monitor immune system responsiveness and 
viral titers in multiple organs at the very earliest stages of infection. Another 
explanation for the observation that no viral replication differences were identified in 
VDR knockout mice could be that while vitamin D has been shown to regulate innate 
and adaptive immune responses in mice (246), some of the classical VDR target 
genes in human are not regulated by VDR in mice. For example, the cathelicidins, a 
family of anti-microbial peptides, are known to be regulated by VDR in human, but not 
in mouse (168). Therefore, the further refinement of the molecular mechanisms used 
by vitamin D to facilitate HCMV replication in monocytes is essential. It is entirely 
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possible that VDR upregulates a set of genes in human monocytes would also 
facilitate CMV replication in the murine system if those same genes were upregulated 
by VDR in mice. RNA-Seq type analysis of Vitamin D/VDR induced gene expression 
in the human and murine systems is likely to reveal important insight into not only the 
mechanism(s) of VDR action but also into the molecular details underlying the onset 
of lytic CMV replication in myeloid cells.  
While, the molecular mechanism(s) that vitamin D employs to facilitate HMCV 
permissive infection in monocytes remains unknown, previous studies indicated that 
the Bcl-6 transcription factor is upregulated in THP-1 cells after vitamin D 
treatment(247,248), and it is known that Bcl-6 can have an opposing effect on several 
of the NF-κB regulated inflammatory genes(249,250). The role of NF-κB in HCMV 
replication is still controversial. Although some studies indicate that NF-κB can 
promote HCMV replication (251-253), others show that activation of NF-κB can inhibit 
HCMV replication (254,255). An explanation for these disparate results may be the 
different methodologies used in each study, or differences in downstream gene 
expression in the exact cell type used in each experiment setting. Therefore, we 
hypothesize that Bcl-6 could play a role in modulating the expression NF-κB 
dependent inflammatory genes that are also triggered upon HCMV infection. Thus, 
Bcl-6 upregulation by Vitamin D could create an environment that more strongly 
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supports HCMV lytic infection in THP-1 cells and primary monocytes. Moreover, Bcl-6 
has been known to polarize macrophages into the M2 subtype which participates in 
dampening immune responsiveness and tissue repair.(256,257) An unrelated study 
demonstrated that the percentage of IE positive cells in TB40E infected M2 
macrophages is about 5 fold higher than that in M1 macrophages (258). Taken 
together, these findings suggest that Bcl-6 activity could trigger a select set of target 
genes thus providing a potential molecular mechanism underlying the onset of HCMV 
lytic replication in myeloid cells. 
   In Chapter III, we demonstrate that YM-254890 compound exhibits a potent 
inhibitory effect that can block cytomegalovirus vGPCR induced Gαq dependent 
signaling pathways. Due to fact that cytomegalovirus vGPCRs expressed on different 
cell types may trigger distinct signaling activities or cause tissue specific responses, 
this inhibitor (and related synthetic compounds like WU-0747) may prove to be 
valuable tools that we could use to explore the signaling pathways and cellular 
responses affecting viral replication in various cell types and in vivo. The information 
gleaned from such studies will help us to correlate cellular responses induced by 
vGPCR signaling with viral replication in those cells and could potentially be exploited 
as novel anti-virals. 
Finally, in Chapter IV, we demonstrated that US28 protein is expressed in HCMV 
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infected monocytes where it can trigger a constitutive Gαq dependent signal. This 
US28 induced constitutive signal promotes monocyte adhesion and 
monocyte-endothelial cell adhesion but inhibits THP-1 chemokinesis. These results 
suggest that US28 may play a role in viral dissemination through modulation of 
monocyte adhesion and migration.  
A potential role for US28 in viral dissemination draws parallels with studies 
involving the MCMV encoded vGPCR M33. Studies with MCMV and M33 have shown 
that deletion of M33 (which like US28 is also a Gαq coupled GPCR) causes a defect 
in viral dissemination to salivary glands(196). Interestingly, insertion of the HCMV 
US28 gene into the M33 null virus genome partially rescues the viral dissemination 
exhibited by loss of M33 (198) suggesting that US28 may similarly participate in viral 
dissemination in that model system.  
Since US28 transcripts can also be detected in hematopoietic and myeloid 
progenitor (27,72), we are keenly interested in pursuing studies aimed at discerning 
the function of US28 in these cell types. Kasumi-3 is a myeloid progenitor cell line that 
has recently been shown to be a useful model to study both latent and permissive 
infection of HCMV (120). We will use this cell line to study the function of US28 in 
myeloid progenitor cells. Based on our studies with Vitamin D in THP-1 cells it is quite 
evident that tipping the balance and driving monocytes into mature monocytes is 
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sufficient to trigger lytic replication. From our signaling studies in THP-1 cell, we can 
demonstrate that US28 signaling can activate protein kinase C, and based on 
previous studies it is clear that PKC is centrally involved in regulation of myeloid cell 
differentiation (243,244). In THP-1 cells, we did not identify significant effect of US28 
on the expression of cell differentiation markers, but whether US28 could influence 
the differentiation of myeloid progenitor cells is an intriguing direction for future studies. 
Kasumi-3 cells will be used to investigate the impact of US28 on cell differentiation.  
A similarly interesting direction for the future study is to examine whether US28 can 
affect latency or reactivation. Previous studies have shown that HCMV can establish 
latency in Kasumi-3 cells, and unlike THP-1 cells, HCMV can be reactivated from 
latency in Kasumi-3 cells (120). Inducible US28 expressing Kasumi-3 cell line will be 
utilized to study the effect of US28 on latency or reactivation. 
   In summary, the future directions discussed briefly in this chapter will provide a 
deeper understanding of the molecular mechanisms underlying the host-pathogen 
interactions, which influence HCMV replication and dissemination in myeloid cells. In 
doing so, we could not only begin to unravel the mechanisms underpinning Vitamin 
D’s effect on HCV replication, but also begin to link viral (i.e. US28) and cellular 
factors (i.e. VDR, Bcl-6, etc) that could be potential targets for novel HCMV 
therapeutics.  
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